

# PATENT COOPERATION TREATY

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

HASELTINE LAKE & CO.  
Imperial House  
15-19 Kingsway  
London WC2B 6UD  
GRANDE BRETAGNE

## PCT

### WRITTEN OPINION

(PCT Rule 66)

Date of mailing (day/month/year) <span style="float: right;">24.01.2000</span>	
Applicant's or agent's file reference HL58501/002/LCH	<b>REPLY DUE</b> <span style="float: right;"><b>within 3 month(s)</b> from the above date of mailing</span>
International application No. PCT/GB99/01461	International filing date (day/month/year) 10/05/1999
Priority date (day/month/year) 08/05/1998	
International Patent Classification (IPC) or both national classification and IPC A61K39/00	
Applicant UNIVERSITY OF BRISTOL et.al	

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.
2. This opinion contains indications relating to the following items:
  - I ☒ Basis of the opinion
  - II ☐ Priority
  - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - IV ☐ Lack of unity of invention
  - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - VI ☒ Certain document cited
  - VII ☐ Certain defects in the international application
  - VIII ☐ Certain observations on the international application
3. The applicant is hereby **invited to reply** to this opinion.
 

**When?** See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

**How?** By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

**Also:** For an additional opportunity to submit amendments, see Rule 66.4.  
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.  
For an informal communication with the examiner, see Rule 66.6.

**If no reply is filed,** the international preliminary examination report will be established on the basis of this opinion.
4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: **08/09/2000.**

Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer / Examiner Luis Alves, D  Formalities officer (incl. extension of time limits) Digusto, M Telephone No. +49 89 2399 2564
---	--



## WRITTEN OPINION

International application No. PCT/GB99/01461

### I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

#### Description, pages:

1-39 as originally filed

#### Claims, No.:

1-37 as originally filed

#### Drawings, sheets:

1/15-15/15 as originally filed

### 2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

### 4. Additional observations, if necessary:

### III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,
- ☒ claims Nos. 1-23, 30-32 and 34-37 with respect to industrial applicability,

because:

- ☒ the said international application, or the said claims Nos. as above relate to the following subject matter which does not require an international preliminary examination (*specify*):

## WRITTEN OPINION

International application No. PCT/GB99/01461

see separate sheet

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

### V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

#### 1. Statement

Novelty (N)	Claims	1-28, 30-35	NO
Inventive step (IS)	Claims	1-37	NO
Industrial applicability (IA)	Claims		

#### 2. Citations and explanations

see separate sheet

### VI. Certain documents cited

#### 1. Certain published documents (Rule 70.10)

and / or

#### 2. Non-written disclosures (Rule 70.9)

see separate sheet

Reference is made to the following documents cited in the International search report:

- D1: HIRST T R ET AL: 'Cholera toxin and related enterotoxins as potent immune modulators.' SOCIETY FOR APPLIED BACTERIOLOGY SYMPOSIUM SERIES, (1998) 27 26S-34S.
- D2: EP-A-0 372 928
- D3: US-A-5 241 053
- D4: ZHANG T ET AL: 'Oral immunization with the dodecapeptide repeat of the serine-rich entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response' INFECTION AND IMMUNITY, US, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 63, no. 4, page 1349-1355.
- D5: WILLIAMS N A ET AL: 'Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.' IMMUNOLOGY TODAY, (1999 FEB) 20 (2) 95-101.
- D6: NASHAR T O ET AL: 'Importance of receptor binding in the immunogenicity, adjuvanticity and therapeutic properties of cholera toxin and Escherichia coli heat-labile enterotoxin.' MEDICAL MICROBIOLOGY AND IMMUNOLOGY, (1998 JUN) 187 (1) 3-10.
- D7: RICHARDS C M ET AL: 'Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency.' JOURNAL OF INFECTIOUS DISEASES, (1998 JUN) 177 (6) 1451-7.
- D8: EP-A-0 919 243
- D9: WO-A-99/36088

**Section III:**

1. Claims 1 to 23, 30 to 32 and 34 to 37 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Section V:

1. The subject-matter of claims 1 to 28 and 30 to 35 does not comply with the requirements of Article 33(2) and (3) PCT.
  - 1.1. D1 discloses the immunomodulatory effects of CtxB and EtxB. D1 discloses the mucosal response obtained with administration of said toxins (see p.28S). The use of said toxins as immune modulators in vaccines is disclosed both as recombinant fusion proteins and as chemical conjugates with antigens (see p. 30S, point 4). Also disclosed is a vaccine comprising glycoproteins from HSV administered with CtxB or EtxB (see p. 30S, left hand column, last paragraph). Thus, D1 discloses the subject-matter of claims 1 to 3, 24, 26 to 28 and 30 to 35 (Article 33(2) PCT).
  - 1.2. D2 discloses EtxB fusion proteins comprising an antigen from a pathogen (see p.2, lines 16 to 54). The fusion proteins can be used as vaccines. Thus, the subject-matter of claims 1 to 26, 30 and 32 does not comply with the requirements of Article 33(2) PCT.
  - 1.3. D3 discloses fusion proteins comprising EtxB and another protein. D3 specifically discloses such a fusion protein comprising antigen from several infectious agents (see abstract, column 1, first paragraph and column 2, lines 20 to 39). Thus, the subject-matter of claims 1 to 7, 9 to 11, 16, 17, 22 to 26, 30 and 32 is disclosed (Article 33(2) PCT).
  - 1.4. D4 discloses a fusion protein comprising CtxB and antigen from *Entamoeba histolytica* and its use in a vaccine for prevention of infection with said parasite (see abstract, p.1349 and p. 1354, left hand column). Thus, the subject-matter of claims 1, 18, 22, 24 and 27 to 32 is disclosed (Article 33(2) PCT).
2. None of the cited documents specifically discloses a kit. However, the subject-matter of claim 29 does not seem to involve an inventive step (Article 33(3) PCT) in view of any of D1 to D4 because it is obvious to provide a kit with the known components for use in the known method.

The subject-matter of claims 36 and 37 concerns a vaccine against EBV and the use

of a vaccine for treatment of an EBV disease, respectively. Since such vaccines and uses are already known for herpes virus (see D1 to D3) the provision of a vaccine and use specific for EBV does not seem to involve an inventive step. Therefore, the subject-matter of claims 36 and 37 does not comply with the requirements of Article 33(3) PCT.

3. Documents D5 to D7, cited in the International search report as an intermediate documents, may be detrimental to the novelty and inventiveness of the subject-matter of the present claims if the priority date of 8 May 1998 is not validly claimed.
4. The subject-matter of claims 24 to 29 and 33 appears to be industrially applicable. For the assessment of the present claims 1 to 23, 30 to 32 and 34 to 37 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Section VI:**

1. Documents D8 and D9 are patent documents cited in the International search report. D8 was published on 2 June 1999 and filed on 25 November 1997. D9 was published on 22 July 1999, filed on 15 January 1999 and claims a priority date of 16 January 1998.

Should the present application be entered into the regional phase, the above documents could be relevant to the question of novelty.

PEPO

# PCT

## CHAPTER II

### DEMAND

under Article 31 of the Patent Cooperation Treaty.  
The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

For International Preliminary Examining Authority use only

Identification of IPEA

Date of receipt of DEMAND

#### Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION

Applicant's or agent's file reference

International application No.

International filing date (day/month/year)

(Earliest) Priority date (day/month/year)

PCT/GB99/01461

10 May 1999 (10.05.99)

8 May 1998 (08.05.98)

Title of invention

VACCINE

#### Box No. II APPLICANT(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Telephone No.:

University of Bristol  
Senate House  
Tyndall Avenue  
Clifton  
Bristol BS8 1TH  
United Kingdom

Facsimile No.:

Teleprinter No.:

State (that is, country) of nationality:

GB

State (that is, country) of residence:

GB

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

HIRST, Timothy Raymond  
30 Albert Road  
Clevedon  
North Somerset  
BS21 7RR  
United Kingdom

State (that is, country) of nationality:

GB

State (that is, country) of residence:

GB

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

WILLIAMS, Neil Andrew  
16 Old Coach Road  
Cross  
Axbridge  
Somerset BS26 2EF  
United Kingdom

State (that is, country) of nationality:

GB

State (that is, country) of residence:

GB



Further applicants are indicated on a continuation sheet.

**III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

Following person is ☐ agent ☒ common representative

☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.

☐ is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.

☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

NASH, David Allan  
 HASELTINE LAKE & CO.  
 Imperial House  
 15-19 Kingsway  
 London WC2B 6UD.  
 United Kingdom

Telephone No.:

0207 420 0500

Facsimile No.:

0207 420 0505

Teleprinter No.:

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

**Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION****Statement concerning amendments:\***

1. The applicant wishes the international preliminary examination to start on the basis of:

☒ the international application as originally filed  
 the description ☒ as originally filed  
☐ as amended under Article 34

the claims ☒ as originally filed  
☐ as amended under Article 19 (together with any accompanying statement)  
☐ as amended under Article 34

the drawings ☒ as originally filed  
☐ as amended under Article 34

2. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.

3. ☐ The applicant wishes the start of the international preliminary examination to be postponed until the expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). *(This check-box may be marked only where the time limit under Article 19 has not yet expired.)*

\* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination English

- ☒ which is the language in which the international application was filed.  
☐ which is the language of a translation furnished for the purposes of international search.  
☐ which is the language of publication of the international application.  
☐ which is the language of the translation (to be) furnished for the purposes of international preliminary examination.

**Box No. V ELECTION OF STATES**

The applicant hereby elects all eligible States *(that is, all States which have been designated and which are bound by Chapter II of the PCT)*

excluding the following States which the applicant wishes not to elect:



**CHECK LIST**

The demand is accompanied by the following elements, in the language referred to in No. IV, for the purposes of international preliminary examination:

- |  |   |   |        |
|--|---|---|--------|
| 1. translation of international application                              | : |   | sheets |
| 2. amendments under Article 34   | : |   | sheets |
| 3. copy (or, where required, translation) of amendments under Article 19 | : |   | sheets |
| 4. copy (or, where required, translation) of statement under Article 19  | : |   | sheets |
| 5. letter  | : | 1 | sheets |
| 6. other (specify) Form 1037   | : | 2 | sheets |

**For International Preliminary Examining Authority use only**

received	not received
----------	--------------

<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>

The demand is also accompanied by the item(s) marked below:

- |  |   |
|--|---|
| 1. <input type="checkbox"/> fee calculation sheet  | 4. <input type="checkbox"/> statement explaining lack of signature                                  |
| 2. <input type="checkbox"/> separate signed power of attorney                            | 5. <input type="checkbox"/> nucleotide and or amino acid sequence listing in computer readable form |
| 3. <input type="checkbox"/> copy of general power of attorney, reference number, if any. | 6. <input type="checkbox"/> other (specify):  |

**Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE**

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

NASH, David Allan  
Authorised Representative.

**For International Preliminary Examining Authority use only**

1. Date of actual receipt of DEMAND:

2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):

3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply.

☐ The applicant has been informed accordingly.

4. ☐ The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5.

5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

**For International Bureau use only**

Demand received from IPEA on:

# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

## PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

To:

HASELTINE LAKE & CO.  
Imperial House  
15-19 Kingsway  
London WC2B 6UD  
UNITED KINGDOM

Date of mailing  
(day/month/year)

15/12/1999

Applicant's or agent's file reference

HL58501/002/LCH

FOR FURTHER ACTION

See paragraphs 3 and 4 below

International application No.

PCT/GB 99/01461

International filing date  
(day/month/year)

10/05/1999

Applicant

UNIVERSITY OF BRISTOL.et.al

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

### Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Barbara Klaver

## PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

HARDING, Charles, Thomas  
D Young & Co.  
Briton House  
Briton Street  
Southampton SO14 3 EB  
ROYAUME-UNI

Date of mailing (day/month/year) 14 November 2000 (14.11.00)	<b>IMPORTANT NOTIFICATION</b>
Applicant's or agent's file reference P009274WO CTH HLB	
International application No. PCT/GB99/01461	International filing date (day/month/year) 10 May 1999 (10.05.99)

1. The following indications appeared on record concerning:		
<input type="checkbox"/> the applicant	<input type="checkbox"/> the inventor	<input checked="" type="checkbox"/> the agent <input type="checkbox"/> the common representative
Name and Address NASH, David, Allan Haseltine Lake & Co. Imperial House 15-19 Kingsway London WC2B 6UD United Kingdom	State of Nationality	State of Residence
	Telephone No. 44 171 405 6093	
	Facsimile No. 44 171 405 0965	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input checked="" type="checkbox"/> the person	<input type="checkbox"/> the name	<input type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence
Name and Address HARDING, Charles, Thomas D Young & Co. Briton House Briton Street Southampton SO14 3 EB United Kingdom	State of Nationality	State of Residence
	Telephone No. 44 23 8071 9500	
	Facsimile No. 44 23 8071 9800	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer R. Chrem
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

## PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

HARDING, Charles, Thomas  
D Young & Co.  
Briton House  
Briton Street  
Southampton SO14 3 EB  
ROYAUME-UNIDate of mailing (day/month/year)  
14 November 2000 (14.11.00)Applicant's or agent's file reference  
P009274WO CTH HLB

## IMPORTANT NOTIFICATION

International application No.  
PCT/GB99/01461International filing date (day/month/year)  
10 May 1999 (10.05.99)

## 1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

State of Nationality

State of Residence

Telephone No.

Facsimile No.

Teleprinter No.

## 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

MORGAN, Andrew  
WILSON, Andrew, Douglas  
BIRD, Lucy, Amber

State of Nationality

GB

State of Residence

GB

Telephone No.

Facsimile No.

Teleprinter No.

## 3. Further observations, if necessary:

**The persons appearing in Box 2 above have been recorded as additional inventors applicants for the US only.**

## 4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned  
☐ the International Searching Authority ☒ the elected Offices concerned  
☒ the International Preliminary Examining Authority ☐ other:The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

R. Chrem

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C. 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 10 December 1999 (10.12.99)	
International application No. PCT/GB99/01461	Applicant's or agent's file reference ML58501/002/LCH
International filing date (day/month/year) 10 May 1999 (10.05.99)	Priority date (day/month/year) 08 May 1998 (08.05.98)
Applicant HIRST, Timothy, Raymond et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

08 November 1999 (08.11.99)

☐ in a notice effecting later election filed with the International Bureau on:
2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Olivia RANAIVOJAONA Telephone No.: (41-22) 338.83.38
---	---

PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum)

HL58501/002/LCH

Box No. I TITLE OF INVENTION  
VACCINE

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

University of Bristol  
Senate House  
Tyndall Avenue  
Clifton  
Bristol BS8 1TH  
United Kingdom

BEST AVAILABLE COPY

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant  
for the purposes of:
☐ all designated  
States

☒ all designated States except  
the United States of America

☐ the United States  
of America only

☐ the States indicated in  
the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HIRST, Timothy Raymond  
30 Albert Road  
Clevedon  
North Somerset  
BS21 7RR  
United Kingdom

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box  
is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

GB

GB

This person is applicant  
for the purposes of:
☐ all designated  
States

☐ all designated States except  
the United States of America

☒ the United States  
of America only

☐ the States indicated in  
the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☐ agent

☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

NASH, David Allan  
HASELTINE LAKE & CO.  
Imperial House  
15-19 Kingsway  
London  
WC2B 6UD  
United Kingdom

Telephone No.

+44 171 405 6093

Facsimile No.

+44 171 405 0965

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

See Notes to the request for

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

WILLIAMS, Neil Andrew  
16 Old Coach Road  
Cross  
Axbridge  
Somerset BS26 2EF  
United Kingdom

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BEST AVAILABLE COPY

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Sheet No. ...3...

## DESIGNATION OF STATES

Designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes: at least one must be marked):

- ☒ **AP** ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA** Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP** European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA** OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- |  |  |
|--|--|
| <input checked="" type="checkbox"/> AL Albania                               | <input checked="" type="checkbox"/> LS Lesotho                                   |
| <input checked="" type="checkbox"/> AM Armenia                               | <input checked="" type="checkbox"/> LT Lithuania                                 |
| <input checked="" type="checkbox"/> AT Austria                               | <input checked="" type="checkbox"/> LU Luxembourg                                |
| <input checked="" type="checkbox"/> AU Australia                             | <input checked="" type="checkbox"/> LV Latvia                                    |
| <input checked="" type="checkbox"/> AZ Azerbaijan                            | <input checked="" type="checkbox"/> MD Republic of Moldova                       |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina                | <input checked="" type="checkbox"/> MG Madagascar                                |
| <input checked="" type="checkbox"/> BB Barbados                              | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BG Bulgaria                              | <input checked="" type="checkbox"/> MN Mongolia                                  |
| <input checked="" type="checkbox"/> BR Brazil                                | <input checked="" type="checkbox"/> MW Malawi                                    |
| <input checked="" type="checkbox"/> BY Belarus                               | <input checked="" type="checkbox"/> MX Mexico                                    |
| <input checked="" type="checkbox"/> CA Canada                                | <input checked="" type="checkbox"/> NO Norway                                    |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein  | <input checked="" type="checkbox"/> NZ New Zealand                               |
| <input checked="" type="checkbox"/> CN China                                 | <input checked="" type="checkbox"/> PL Poland                                    |
| <input checked="" type="checkbox"/> CU Cuba                                  | <input checked="" type="checkbox"/> PT Portugal                                  |
| <input checked="" type="checkbox"/> CZ Czech Republic                        | <input checked="" type="checkbox"/> RO Romania                                   |
| <input checked="" type="checkbox"/> DE Germany                               | <input checked="" type="checkbox"/> RU Russian Federation                        |
| <input checked="" type="checkbox"/> DK Denmark                               | <input checked="" type="checkbox"/> SD Sudan                                     |
| <input checked="" type="checkbox"/> EE Estonia                               | <input checked="" type="checkbox"/> SE Sweden                                    |
| <input checked="" type="checkbox"/> ES Spain                                 | <input checked="" type="checkbox"/> SG Singapore                                 |
| <input checked="" type="checkbox"/> FI Finland                               | <input checked="" type="checkbox"/> SI Slovenia                                  |
| <input checked="" type="checkbox"/> GB United Kingdom                        | <input checked="" type="checkbox"/> SK Slovakia                                  |
| <input checked="" type="checkbox"/> GD Grenada                               | <input checked="" type="checkbox"/> SL Sierra Leone                              |
| <input checked="" type="checkbox"/> GE Georgia                               | <input checked="" type="checkbox"/> TJ Tajikistan                                |
| <input checked="" type="checkbox"/> GH Ghana                                 | <input checked="" type="checkbox"/> TM Turkmenistan                              |
| <input checked="" type="checkbox"/> GM Gambia                                | <input checked="" type="checkbox"/> TR Turkey                                    |
| <input checked="" type="checkbox"/> HR Croatia                               | <input checked="" type="checkbox"/> TT Trinidad and Tobago                       |
| <input checked="" type="checkbox"/> HU Hungary                               | <input checked="" type="checkbox"/> UA Ukraine                                   |
| <input checked="" type="checkbox"/> ID Indonesia                             | <input checked="" type="checkbox"/> UG Uganda                                    |
| <input checked="" type="checkbox"/> IL Israel                                | <input checked="" type="checkbox"/> US United States of America                  |
| <input checked="" type="checkbox"/> IN India                                 | <input checked="" type="checkbox"/> UZ Uzbekistan                                |
| <input checked="" type="checkbox"/> IS Iceland                               | <input checked="" type="checkbox"/> VN Viet Nam                                  |
| <input checked="" type="checkbox"/> JP Japan                                 | <input checked="" type="checkbox"/> YU Yugoslavia                                |
| <input checked="" type="checkbox"/> KE Kenya                                 | <input checked="" type="checkbox"/> ZW Zimbabwe                                  |
| <input checked="" type="checkbox"/> KG Kyrgyzstan                            |  |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea |  |
| <input checked="" type="checkbox"/> KR Republic of Korea                     |  |
| <input checked="" type="checkbox"/> KZ Kazakhstan                            | <input checked="" type="checkbox"/> AE United Arab Emirates                      |
| <input checked="" type="checkbox"/> LC Saint Lucia                           | <input checked="" type="checkbox"/> ZA South Africa                              |
| <input checked="" type="checkbox"/> LK Sri Lanka                             |  |
| <input checked="" type="checkbox"/> LR Liberia                               |  |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

See Notes to the request form



PRIORITY		Further priority claims are indicated in the Supplemental Box.		
Date of application (month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application: regional Office	international application: receiving Office
08/05/98	9809958.3	GB		
05/06/98	9811954.8	GB		
08/06/98	9812316.9	GB		

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1)

\* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

**Box No. VII INTERNATIONAL SEARCHING AUTHORITY**

Choice of International Searching Authority (ISA) (If two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen: the two-letter code may be used): <b>ISA / EP</b>	Request to use results of earlier search: reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority): Date (day/month/year) _____ Number _____ Country (or regional Office) _____
--	---

**Box No. VIII CHECK LIST: LANGUAGE OF FILING**

This international application contains the following number of sheets: request : 4 description (excluding sequence listing part) : 39 claims : 7 abstract : 1 drawings : 15 sequence listing part of description : - Total number of sheets : 66	This international application is accompanied by the item(s) marked below: 1. <input checked="" type="checkbox"/> fee calculation sheet 2. <input type="checkbox"/> separate signed power of attorney 3. <input type="checkbox"/> copy of general power of attorney, reference number, if any: 4. <input type="checkbox"/> statement explaining lack of signature 5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s): 6. <input type="checkbox"/> translation of international application into (language): 7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material 8. <input type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form 9. <input type="checkbox"/> other (specify):
--	--

Figure of the drawings which should accompany the abstract: \_\_\_\_\_ Language of filing of the international application: **English**

**Box No. IX SIGNATURE OF APPLICANT OR AGENT**

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

**SILVERMAN, Warren**

BEST AVAILABLE COPY

For receiving Office use only		2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
1. Date of actual receipt of the purported international application:		
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		
4. Date of timely receipt of the required corrections under PCT Article 11(2):		
5. International Searching Authority (if two or more are competent): <b>ISA /</b>	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.	

Date of receipt of the record copy by the International Bureau:	For International Bureau use only
---	-----------------------------------

Form PCT/RO/101 (last sheet) (July 1998; reprint January 1999)

See Notes to the request form

15/11 '00 16:18 FAX 41 22 740 14

PCT EXAM SECTION 1

003/003

## PATENT COOPERATION TREATY

09/701850 #3

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

HARDING, Charles, Thomas  
D Young & Co.  
Briton House  
Briton Street  
Southampton SO14 3 EB  
ROYAUME-UNIDate of mailing (day/month/year)  
14 November 2000 (14.11.00)Applicant's or agent's file reference  
P009274WO CTH HLBInternational application No.  
PCT/GB99/01461

## IMPORTANT NOTIFICATION

International filing date (day/month/year)  
10 May 1999 (10.05.99)

1. The following indications appeared on record concerning:

☐ the applicant☐ the inventor☐ the agent☐ the common representative

Name and Address

State of Nationality

State of Residence

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person☐ the name☐ the address☐ the nationality☐ the residence

Name and Address

MORGAN, Andrew  
WILSON, Andrew, Douglas  
BIRD, Lucy, Amber

State of Nationality

GB

State of Residence

GB

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

The persons appearing in Box 2 above have been recorded as additional inventors applicants  
for the US only.

4. A copy of this notification has been sent to:

☒ the receiving Office☐ the International Searching Authority☒ the International Preliminary Examining Authority☐ the designated Offices concerned☒ the elected Offices concerned☐ other:The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.1435

Authorized officer

R. Chrem

Telephone No.: (41-22) 338.83.38

003657724

15/11 '00 18:18 FAX 41 22 740 14

## PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

HARDING, Charles, Thomas  
D Young & Co.  
Briton House  
Briton Street  
Southampton SO14 3 EB  
ROYAUME-UNI

Date of mailing (day/month/year)

14 November 2000 (14.11.00)

Applicant's or agent's file reference

P003274WO CTH HLB

## IMPORTANT NOTIFICATION

International application No.

PCT/GB99/01461

International filing date (day/month/year)

10 May 1999 (10.05.99)

## 1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☒ the agent ☐ the common representative

Name and Address

NASH, David, Allan  
Haseltine Lake & Co.  
Imperial House  
15-19 Kingsway  
London WC2B 6UD  
United Kingdom

State of Nationality

State of Residence

Telephone No.

44 171 405 6093

Facsimile No.

44 171 405 0965

Teleprinter No.

## 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

HARDING, Charles, Thomas  
D Young & Co.  
Briton House  
Briton Street  
Southampton SO14 3 EB  
United Kingdom

State of Nationality

State of Residence

Telephone No.

44 23 8071 9500

Facsimile No.

44 23 8071 9800

Teleprinter No.

## 3. Further observations, if necessary:

## 4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned  
☐ the International Searching Authority ☒ the elected Offices concerned  
☒ the International Preliminary Examining Authority ☐ other:The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

R. Chrem

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

**TENT COOPERATION TREATY**

**PCT**

**INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>HL58501/002/LCH</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 99/ 01461</b>	International filing date (day/month/year) <b>10/05/1999</b>	(Earliest) Priority Date (day/month/year) <b>08/05/1998</b>
Applicant <b>UNIVERSITY OF BRISTOL.et.al</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**IMMUNOMODULATORS FOR VACCINES**

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/01461

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark: Although claims 1-23,30,31,34 and 35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

National Application No

PCT/GB 99/01461

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K39/12 A61K38/16 A61K39/245 A61K39/385

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 02045 A (UNIVERSITY OF BRISTOL) 23 January 1997 (1997-01-23) cited in the application page 44 -page 46 ---	1-36
Y	NASHAR T O ET AL: "Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1." IMMUNOLOGY, (1997 AUG) 91 (4) 572-8. , XP002123821 the whole document --- -/--	1-36

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## ° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

25 November 1999

Date of mailing of the international search report

15/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01461

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HIRST T R ET AL: "Cholera toxin and related enterotoxins as potent immune modulators." SOCIETY FOR APPLIED BACTERIOLOGY SYMPOSIUM SERIES, (1998) 27 26S-34S, XP000856429 the whole document ---	1-36
X	EP 0 372 928 A (UNIVERSITY OF LEICESTER) 13 June 1990 (1990-06-13) claims 1-14 ---	1,24, 28-30
X	US 5 241 053 A (FUJISAWA Y. ET AL.) 31 August 1993 (1993-08-31) the whole document ---	1,24, 28-30
X	ZHANG T ET AL: "ORAL IMMUNIZATION WITH THE DODECAPEPTIDE REPEAT OF THE SERINE-RICH ENTAMOEBA HISTOLYTICA PROTEIN (SREHP) FUSED TO THE CHOLERA TOXIN B SUBUNIT INDUCES A MUCOSAL AND SYSTEMIC ANTI-SREHP ANTIBODY RESPONSE" INFECTION AND IMMUNITY, US, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, vol. 63, no. 4, page 1349-1355 XP000645273 ISSN: 0019-9567 the whole document ---	1,22,24, 26,28-30
P,X	WILLIAMS N A ET AL: "Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic." IMMUNOLOGY TODAY, (1999 FEB) 20 (2) 95-101, XP002123822 the whole document ---	1-36
P,X	NASHAR T O ET AL: "Importance of receptor binding in the immunogenicity, adjuvanticity and therapeutic properties of cholera toxin and Escherichia coli heat-labile enterotoxin." MEDICAL MICROBIOLOGY AND IMMUNOLOGY, (1998 JUN) 187 (1) 3-10, XP000857029 the whole document ---	1-36
P,X	RICHARDS C M ET AL: "Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency." JOURNAL OF INFECTIOUS DISEASES, (1998 JUN) 177 (6) 1451-7. , XP002123823 cited in the application the whole document ---	1-36
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01461

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	EP 0 919 243 A (DUPHAR INTERNATIONAL RESEARCH) 2 June 1999 (1999-06-02) the whole document ---	1-36
E	WO 99 36088 A (MAXIM PHARMACEUTICALS) 22 July 1999 (1999-07-22) the whole document -----	1-36



# INTERNATIONAL SEARCH REPORT

ation on patent family members

International Application No

PCT/GB 99/01461

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9702045	A	23-01-1997	AU 6314296	A	05-02-1997
			CA 2225788	A	23-01-1997
			CN 1192693	A	09-09-1998
			CZ 9800012	A	17-06-1998
			EP 0841939	A	20-05-1998
			HU 9900147	A	28-05-1999
			JP 11508586	T	27-07-1999
			NO 980005	A	05-03-1998
			PL 324424	A	25-05-1998
EP 372928	A	13-06-1990	AU 4754490	A	26-06-1990
			CA 2004738	A	07-06-1990
			WO 9006366	A	14-06-1990
			PT 92511	A	29-06-1990
US 5241053	A	31-08-1993	NONE		
EP 919243	A	02-06-1999	AU 1875099	A	15-06-1999
			WO 9926654	A	03-06-1999
WO 9936088	A	22-07-1999	AU 2232399	A	02-08-1999

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

HASELTINE LAKE & CO.  
Imperial House  
15-19 Kingsway  
London WC2B 6UD  
GRANDE BRETAGNE

DAN.

PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT  
(PCT Rule 71.1)

Date of mailing  
(day/month/year) 10.07.2000

Applicant's or agent's file reference  
HL58501/002/LCH

IMPORTANT NOTIFICATION

International application No.  
PCT/GB99/01461

International filing date (day/month/year)  
10/05/1999

Priority date (day/month/year)  
08/05/1998

Applicant  
UNIVERSITY OF BRISTOL et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Digiusto, M

Tel. +49 89 2399-8162



REC'D 12 JUL 2000

WIPO

PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference HL58501/002/LCH	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB99/01461	International filing date (day/month/year) 10/05/1999	Priority date (day/month/year) 08/05/1998
International Patent Classification (IPC) or national classification and IPC A61K39/00		
Applicant UNIVERSITY OF BRISTOL.et.al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  08/11/1999	Date of completion of this report  10.07.2000
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Luis Alves, D  Telephone No. +49 89 2399 8695 

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/01461

## I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

### Description, pages:

1-39 as originally filed

### Claims, No.:

1-37 as originally filed

### Drawings, sheets:

1/15-15/15 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

## III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 1-23, 30-32 and 34-37 with respect to industrial applicability.

because:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/01461

- ☒ the said international application, or the said claims Nos. as above relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

- ☐ no international search report has been established for the said claims Nos. .

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims	29, 36, 37
	No:	Claims	1-28, 30-35
Inventive step (IS)	Yes:	Claims	.
	No:	Claims	1-37
Industrial applicability (IA)	Yes:	Claims	24-29, 33
	No:	Claims	.

### 2. Citations and explanations

**see separate sheet**

## VI. Certain documents cited

### 1. Certain published documents (Rule 70.10)

and / or

### 2. Non-written disclosures (Rule 70.9)

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB99/01461

Reference is made to the following documents cited in the International search report:

D1: HIRST T R ET AL: 'Cholera toxin and related enterotoxins as potent immune modulators.' SOCIETY FOR APPLIED BACTERIOLOGY SYMPOSIUM SERIES, (1998) 27 26S-34S.

D2: EP-A-0 372 928

D3: US-A-5 241 053

D4: ZHANG T ET AL: 'Oral immunization with the dodecapeptide repeat of the serine-rich entamoeba histolytica protein (SREHP) fused to the cholera toxin B subunit induces a mucosal and systemic anti-SREHP antibody response' INFECTION AND IMMUNITY, US, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 63, no. 4, page 1349-1355.

D5: WILLIAMS N A ET AL: 'Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.' IMMUNOLOGY TODAY, (1999 FEB) 20 (2) 95- 101.

D6: NASHAR T O ET AL: 'Importance of receptor binding in the immunogenicity, adjuvanticity and therapeutic properties of cholera toxin and Escherichia coli heat-labile enterotoxin.' MEDICAL MICROBIOLOGY AND IMMUNOLOGY, (1998 JUN) 187 (1) 3-10.

D7: RICHARDS C M ET AL: 'Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency.' JOURNAL OF INFECTIOUS DISEASES, (1998 JUN) 177 (6) 1451- 7.

D8: EP-A-0 919 243

D9: WO-A-99/36088

**Section III:**

1. Claims 1 to 23, 30 to 32 and 34 to 37 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB99/01461

**Section V:**

1. The subject-matter of claims 1 to 28 and 30 to 35 does not comply with the requirements of Article 33(2) and (3) PCT.
  - 1.1. D1 discloses the immunomodulatory effects of CtxB and EtxB. D1 discloses the mucosal response obtained with administration of said toxins (see p.28S). The use of said toxins as immune modulators in vaccines is disclosed both as recombinant fusion proteins and as chemical conjugates with antigens (see p. 30S, point 4). Also disclosed is a vaccine comprising glycoproteins from HSV administered with CtxB or EtxB (see p. 30S, left hand column, last paragraph). Thus, D1 discloses the subject-matter of claims 1 to 3, 24, 26 to 28 and 30 to 35 (Article 33(2) PCT).
  - 1.2. D2 discloses EtxB fusion proteins comprising an antigen from a pathogen (see p.2, lines 16 to 54). The fusion proteins can be used as vaccines. Thus, the subject-matter of claims 1 to 26, 30 and 32 does not comply with the requirements of Article 33(2) PCT.
  - 1.3. D3 discloses fusion proteins comprising EtxB and another protein. D3 specifically discloses such a fusion protein comprising antigen from several infectious agents (see abstract, column 1, first paragraph and column 2, lines 20 to 39). Thus, the subject-matter of claims 1 to 7, 9 to 11, 16, 17, 22 to 26, 30 and 32 is disclosed (Article 33(2) PCT).
  - 1.4. D4 discloses a fusion protein comprising CtxB and antigen from *Entamoeba histolytica* and its use in a vaccine for prevention of infection with said parasite (see abstract, p.1349 and p. 1354, left hand column). Thus, the subject-matter of claims 1, 18, 22, 24 and 27 to 32 is disclosed (Article 33(2) PCT).
2. None of the cited documents specifically discloses a kit. However, the subject-matter of claim 29 does not seem to involve an inventive step (Article 33(3) PCT) in view of any of D1 to D4 because it is obvious to provide a kit with the known components for use in the known method.

The subject-matter of claims 36 and 37 concerns a vaccine against EBV and the use

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB99/01461

of a vaccine for treatment of an EBV disease, respectively. Since such vaccines and uses are already known for herpes virus (see D1 to D3) the provision of a vaccine and use specific for EBV does not seem to involve an inventive step. Therefore, the subject-matter of claims 36 and 37 does not comply with the requirements of Article 33(3) PCT.

3. Documents D5 to D7, cited in the International search report as an intermediate documents, may be detrimental to the novelty and inventiveness of the subject-matter of the present claims if the priority date of 8 May 1998 is not validly claimed.
4. The subject-matter of claims 24 to 29 and 33 appears to be industrially applicable. For the assessment of the present claims 1 to 23, 30 to 32 and 34 to 37 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Section VI:**

1. Documents D8 and D9 are patent documents cited in the International search report. D8 was published on 2 June 1999 and filed on 25 November 1997. D9 was published on 22 July 1999, filed on 15 January 1999 and claims a priority date of 16 January 1998.

Should the present application be entered into the regional phase, the above documents could be relevant to the question of novelty.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/58145</b> <b>(43) International Publication Date:</b> 18 November 1999 (18.11.99)									
<b>(21) International Application Number:</b> PCT/GB99/01461 <b>(22) International Filing Date:</b> 10 May 1999 (10.05.99)  <b>(30) Priority Data:</b> <table border="0"> <tr> <td>9809958.3</td> <td>8 May 1998 (08.05.98)</td> <td>GB</td> </tr> <tr> <td>9811954.8</td> <td>3 June 1998 (03.06.98)</td> <td>GB</td> </tr> <tr> <td>9812316.9</td> <td>8 June 1998 (08.06.98)</td> <td>GB</td> </tr> </table> <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF BRISTOL [GB/GB]; Senate House, Tyndall Avenue, Clifton, Bristol BS8 1TH (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HIRST, Timothy, Raymond [GB/GB]; 30 Albert Road, Clevedon, North Somerset BS21 7RR (GB). WILLIAMS, Neil, Andrew [GB/GB]; 16 Old Coach Road, Cross, Axbridge, Somerset BS26 2EF (GB).  <b>(74) Agent:</b> NASH, David, Allan; Haseltine Lake & Co., Imperial House, 15-19 Kingsway, London WC2B 6UD (GB).		9809958.3	8 May 1998 (08.05.98)	GB	9811954.8	3 June 1998 (03.06.98)	GB	9812316.9	8 June 1998 (08.06.98)	GB	<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
9809958.3	8 May 1998 (08.05.98)	GB									
9811954.8	3 June 1998 (03.06.98)	GB									
9812316.9	8 June 1998 (08.06.98)	GB									
<b>(54) Title:</b> VACCINE  <b>(57) Abstract</b> <p>There is disclosed the use of: (i) EtxB, CtxB or VtxB free from whole toxin; (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding; as an immunomodulator for a vaccine against infectious diseases.</p>											

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

**VACCINE**

This invention relates to an immunomodulator for use in a vaccine which is intended for use against a range of infectious agents. Further this invention  
5 relates to a vaccine composition comprising the immunomodulator, preferably in combination with antigen and a vaccination method using the vaccine composition.

Cholera toxin (Ctx) and its close relative E. coli heat-labile enterotoxin (Etx) are potent immunogens and  
10 mucosal adjuvants. However, their inherent toxicity makes them unsuitable for human use. For example, although Ctx is the most commonly used mucosal adjuvant in experimental animals, it is unsuitable for use in humans because of its potent diarrhoea-inducing  
15 properties. Attempts have been made to separate toxicity from adjuvant activity, for example by using components of Ctx and Etx as replacements for the holotoxins themselves. E. coli verotoxin (Vtx) is another known bacterial toxin.

Ctx and Etx are heterohexameric proteins composed  
20 of a an enzymatically active A subunit and a pentameric B subunit. CtxB and EtxB are known to bind GM1-ganglioside (GM1), a glycosphingolipid found ubiquitously on the surface of mammalian cells. Vtx  
25 binds to Gb3 which is a similar type of receptor to GM1.

In an attempt to circumvent the problem of toxicity for vaccine development, the adjuvant activity of the non-toxic B subunits has previously been  
30 investigated. However, many of the reports describe experiments in which a commercial preparation of CtxB or EtxB was used. These preparations are inevitably contaminated with a small but biologically significant amount of active toxin, so the adjuvant activity  
35 attributable to the B subunit is indistinguishable from the adjuvant activity of the whole toxin (Wu and

-2-

Russell (1993) *Infection and Immunity* 61: 314-322, US-5182109). Subsequent studies using recombinant CtxB (rCtxB) have suggested that CtxB is a poor mucosal adjuvant and only the addition of native holotoxin can  
5 provoke strong bystander responses (Tamura et al (1994) *Vaccine* 12: 419-426). Other studies have suggested that rCtxB lacks the ADP-ribosylating and the cAMP-stimulating activities of the holotoxin and that, as  
10 adjuvant mechanism is linked to these abilities, CtxB would be unsuitable for use as an adjuvant (Vajdy and Lycke (1992) *Immunology* 75: 488-492, Lycke et al (1992) *Eur. J. Immunol.* 22: 2277-2281, Douce et al (1997) *Infection and Immunity* 65: 2821-2828).

In another study, intranasal administration of  
15 ovalbumin using rCtxB as an adjuvant resulted in poor antibody responses. A non-toxic derivative of Ctx with a mutation in the A subunit also generated weak responses to bystander antigens, whereas the presence of an active A subunit dramatically enhanced adjuvant  
20 activity, suggesting that an active A subunit is essential (Douce et al (1997) as above).

It has also been shown that rCtxB and rCtxA can be used to promote tolerance to heterologous antigens (Sun et al (1994) *Proc. Natl. Acad. Sci.* 91: 4610-4614, Sun  
25 et al (1996) *Proc. Natl. Acad. Sci.* 93: 7196-7201, Bergerot et al (1997) *Proc. Natl. Acad. Sci.* 94: 4610-4614, Williams et al (1997) *Proc. Natl. Acad. Sci.* 94: 5290-5295), suggesting that these molecules would be unsuitable for use as adjuvants.

### The basis of the present invention

30 In spite of the teaching in the art that CtxB and EtxB have poor adjuvanticity and can, in fact, act as tolerogens, the present inventors nevertheless

-3-

investigated the use of rEtxB (thus containing no residual holotoxin or A subunit) in an intranasal vaccine for HSV in a murine model and surprisingly found that it is able to stimulate protective immune responses to viral challenge. Specifically, the present inventors found that:

- i) agents such as EtxB and CtxB stimulate high levels of local (mucosal) antibody production (although immunization using rEtxB stimulated lower levels of overall serum antibody production than Ctx/CtxB combined);
- ii) the distribution of antibodies produced was skewed towards non-complement fixing antibodies, especially S-IgA and IgG1;
- iii) agents such as EtxB and CtxB also stimulated local and systemic T-cell proliferative responses;
- iv) agents such as CtxB and EtxB tend to shift the immune response from a Th1-associated response to a Th2-associated response;
- v) when agents such as CtxB and EtxB are used as immunomodulators some of the harmful effects of Th2-associated responses, such as the generation of IgE, are avoided;
- vi) rEtxB is a more efficient immunomodulator than rCtxB;
- vii) agents such as EtxB and CtxB are capable of altering the way in which an antigen presenting cell internalises and processes antigen, increasing antigen persistence;
- viii) if an agent such as EtxB and CtxB is linked to an antigen, it is possible to alter the processing route of the antigen by altering the linkage to the immunomodulator; and
- ix) VtxB exerts similar immunomodulatory effects on leukocyte populations in vitro to those exerted by EtxB and CtxB.

-4-

These important discoveries are the basis of the various aspects of the present invention and enabled the inventors to predict that pure EtxB, CtxB and VtxB, as well as other agents capable of binding to or  
5 mimicking the effect of binding to GM1 or Gb3, will be useful as immunomodulators for use in vaccines in the prophylactic and therapeutic vaccination against HSV-1 infection, as well as other infections, the prevention or treatment of which would benefit from  
10 immunomodulation of the types listed above.

#### Stimulation of immune responses

EtxB, CtxB, VtxB and other agents capable of binding to or mimicking the effects of binding to GM1  
15 or Gb3, are capable of acting as immunomodulators and stimulate specific immune responses to antigenic challenge.

According to a first aspect of the present invention, there is provided the use of:

- 20 (i) EtxB, CtxB or VtxB free from whole toxin;  
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or  
(iii) an agent having an effect on intracellular  
25 signalling events mediated by GM1-binding or Gb3 binding;  
as an immunomodulator for a vaccine against infectious diseases.

According to a second aspect of the present invention, there is provided a vaccine composition for  
30 use against an infectious disease, which infectious disease is caused by an infectious agent, wherein the vaccine composition comprises an antigenic determinant and an immunomodulator selected from:

- 35 (i) EtxB, CtxB or VtxB free from whole toxin;  
(ii) an agent other than EtxB or CtxB, having

-5-

GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

- (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding;

wherein said antigenic determinant is an antigenic determinant of said infectious agent.

The antigen and immunomodulator may be linked, for example covalently or genetically linked, to form a single effective agent. In a specific embodiment of this invention the antigen and immunomodulator may be chemically conjugated. For example, the antigen and immunomodulator may be chemically conjugated using heterobifunctional cross-linking reagents. In most applications of this aspect of the invention, separate administration (in which the antigen and immunomodulator are not so linked) is preferred because it enables separate administration of the different moieties.

According to a third aspect of the present invention, there is provided a kit for vaccination of a mammalian subject, such as a human or veterinary subject, against an infectious disease, comprising:

- a) one of the following agents:
- (i) EtxB, CtxB or VtxB free from whole toxin;
  - (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
  - (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding; and
- b) an antigenic determinant which is an antigenic determinant of the infectious disease, for coadministration with the said vaccine immunomodulator.

The vaccine composition of the second aspect of the invention and the kit of the third aspect of the

-6-

invention may be used in a prophylactic or therapeutic vaccination method, where a "prophylactic vaccine" is administered to naive individuals to prevent disease development, and a "therapeutic vaccine" is  
5 administered to individuals with an existing infection to reduce or minimise the infection or to abrogate the immunopathological consequences of the disease.

Agents such as EtxB have the capacity to alter the nature of the immune response once infection has  
10 occurred. A therapeutic vaccine (i.e. one which need not contain antigen) comprising such an agent may find particular use in circumstances in which the immune response has failed to get rid of an infection. This application may be of particular use to treat a chronic  
15 disease, for example a disease for which the causative agent is selected from the group consisting of herpes viruses, hepatitis viruses, HIV, TB and parasites.

According to a fourth aspect of the present invention there is provided a method of preventing or  
20 treating a disease in a host, which method comprises the step of inoculating said host with a vaccine comprising at least one antigenic determinant and an immunomodulator, where the immunomodulator is:

- (i) EtxB, CtxB or VtxB free from whole toxin;
- 25 (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
- (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3  
30 binding.

The vaccine may be packaged for coadministration and may be administered by a number of different routes such as intranasal, oral, intra-vaginal, urethral or ocular administration. Intranasal immunisation is  
35 presently preferred. When a vaccine is administered intranasally, it may be administered as an aerosol or



-7-

in liquid form.

The antigenic determinant and immunomodulator may be administered to the subject as a single dose or in multiple doses.

5           In a first embodiment the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a disease for  
10           which the infectious agent is a member of the herpes virus family. For example, the infectious agent may be selected from the group consisting of HSV-1, HSV-2, EBV, VZV, CMV, HHV-6, HHV-7 and HHV-8. In particular, the infectious agent may be HSV-1, HSV-2, CMV or EBV.

15           In this first embodiment, the antigenic determinant is preferably an antigenic determinant of an immediate early, early or late gene product (for example a surface glycoprotein) of the herpes virus.

20           If the infectious agent is HSV-1 or HSV-2, the antigenic determinant may be an antigenic determinant of a gene product selected from the following group: gD, gB, gH, gC or a latency associated transcript (LAT).

25           If the infectious agent is EBV, the antigenic determinant may be an antigenic determinant of gp340 or gp350 or of a latent protein (for example EBNA1, 2, 3A, 3B, 3C and -LP, LMP-1, -2A and 2B or an EBER).

30           In a second embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a disease for which the infectious agent is an influenza virus.

35           In this second embodiment, the antigenic determinant is preferably an antigenic determinant of a viral coat protein (for example haemagglutinin and

-8-

neuraminidase) or of an internal protein (for example, nucleoprotein).

5 In a third embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a disease for which the infectious agent is a parainfluenza virus.

10 In a fourth embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a disease for which the infectious agent is respiratory syncytial virus.

15 In a fifth embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a disease for which the infectious agent is a hepatitis virus. For example, the infectious agent may be selected from the group consisting of hepatitis A, B, C and D. In particular the infectious agent may be hepatitis A or C.

20 In a sixth embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against meningitis. In this sixth embodiment, the infectious agent may be selected from the group consisting of *Neisseria meningitidis*, *Haemophilus influenzae* type B and *Streptococcus pneumoniae*.

35 In a seventh embodiment, the immunomodulator of

-9-

the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against pneumonia or a respiratory tract infection. In this seventh embodiment, the infectious agent may be selected from the group consisting of *Streptococcus pneumoniae*, *Legionella pneumophila* and *Mycobacterium tuberculosis*.

In an eighth embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a sexually-transmitted disease. In this eighth embodiment, the infectious agent may be selected from the group consisting of *Neisseria gonorrhoeae*, HIV-1, HIV-2 and *Chlamydia trachomatis*.

In an ninth embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a gastrointestinal disease. In this ninth embodiment, the infectious agent may be selected from the group consisting of enteropathogenic, enterotoxigenic and enteroinvasive *E.coli*, rotavirus, *Salmonella enteritidis*, *Salmonella typhi*, *Helicobacter pylori*, *Bacillus cereus*, *Campylobacter jejuni* and *Vibrio cholerae*.

If the infectious agent is selected from the group consisting of enteropathogenic, enterotoxigenic, enteroinvasive, enterohaemorrhagic and enteroaggregative *E.coli*, then the antigenic determinant may be an antigenic determinant of a

-10-

bacterial toxin or adhesion factor.

In a tenth embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a superficial infection. In this tenth embodiment, the infectious agent may be selected from the group consisting of *Staphylococcus aureus*, *Streptococcus pyogenes* and *Streptococcus mutans*.

In an eleventh embodiment, the immunomodulator of the first aspect of the invention, the vaccine of the second aspect of the invention, the kit of the third aspect of the invention and the method of the fourth aspect of the invention is used against a parasitic disease. In this eleventh embodiment, the infectious agent may be selected from the group consisting of malaria, *Trypanasoma* spp., *Toxoplasma gondii*, *Leishmania donovani* and *Oncocerca* spp.

20

#### Stimulation of mucosal immune responses

EtxB, CtxB, VtxB and other agents capable of binding to or mimicking the effects of binding to GM1 or Gb3, are capable of specifically upregulating mucosal antibody production.

The vaccine immunomodulator of the first aspect of the invention, the vaccine composition of the second aspect of the invention and the kit of the third aspect of the invention are particularly effective against diseases where protection from infection or treatment is effected *in vivo* by a mucosal immune response. For example, against diseases in which, during infection, the infectious agent binds to, colonises or gains access across the mucosa. Examples of such diseases include, diseases caused by viruses (HIV, HSV, EBV,

35

-11-

CMV, influenza, measles, mumps, rotavirus etc), diseases caused by bacteria (E. coli, Salmonella, Shigella, Chlamydia, N. gonorrhoea, T. pallidum, Streptococcus species including those which cause dental caries), and diseases caused by parasites.

In a preferred embodiment of the second aspect of the present invention there is provided a vaccine against HSV-1 infection comprising at least one HSV-1 antigenic determinant and an immunomodulator, where the immunomodulator is:

- (i) EtxB, CtxB or VtxB free from whole toxin;
- (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
- (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or G3b binding.

Preferably the immunomodulator is EtxB.

In a preferred embodiment of the third aspect of the present invention there is provided a kit for vaccination of a mammalian subject against an HSV-1, comprising:

- a) a vaccine immunomodulator which is:
  - (i) EtxB, CtxB or VtxB free from whole toxin;
  - (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
  - (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or G3b binding; and
- b) at least one HSV-1 antigenic determinant, for coadministration with the said vaccine immunomodulator.

According to a fifth aspect of the invention there is provided the use of:

- (i) EtxB, CtxB or VtxB free from whole toxin;

-12-

(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

5 (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding

to upregulate the production of antibodies at mucosal surfaces. The production of non-complement-fixing serum antibodies may also be upregulated.  
10 Preferably, S-IgA is produced in accordance with the fifth aspect of the invention.

In this fifth aspect of the present invention, the agent may be used in conjunction with one or more antigenic determinant(s).

15

Downregulating the pathological components of immune responses

The inventors also found that when pure EtxB was used as an immunomodulator in the described way, the  
20 harmful effects of Th2 associated responses, such as the generation of high levels of potentially pathological IgE, were avoided. Despite this, the immune response triggered by the use of EtxB (or CtxB or VtxB) as an immunomodulator appears to favour the  
25 induction of Th2-associated cytokines. In other words EtxB (or CtxB) induces a shift from a Th1- to a Th2-type response. This has enabled the inventors to predict that pure EtxB, CtxB or VtxB, as well as other agents capable of binding to or mimicking the effect of  
30 binding to GM1 or Gb3, will be capable of down regulating pathological components of the immune response associated with both Th1 and Th2 activation.

According to a sixth aspect of the present invention, there is provided the use of:

- 35 (i) EtxB, CtxB or VtxB free from whole toxin;  
(ii) an agent other than EtxB or CtxB, having

-13-

GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

(iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding;

to downregulate the pathological components of Th2-associated immune responses. The pathological components of Th1-associated immune responses may also be downregulated.

It is known that EtxB and CtxB bind to GM1 and induce differential effects on lymphocyte populations, including a specific depletion of CD8+ T cells and an associated activation of B cells (WO 97/02045). Hence, EtxB and CtxB are thought to alter the balance of the immune response such that inflammatory Th1 associated reactions are down-regulated while Th2 associated responses are upregulated. Th1 responses include the secretion of  $\gamma$ IFN by activated T-cells leading to macrophage activation and delayed type hypersensitivity reactions. Such responses may be an important cause of pathology during infections with a number of pathogens. Th2 responses include the activation of T-cells to produce cytokines such as IL-4, IL-5, IL-10, and are known to promote the secretion of high levels of antibody, especially IgA.

It has now surprisingly been found that when EtxB is used as an immunomodulator in the described way, the harmful effects of Th2 associated responses, such as the generation of high levels of potentially pathological IgE, are avoided. Therefore, EtxB and CtxB are capable of down regulating pathological components of the immune response associated both with Th1 and Th2 activation. Such responses are modulated in favour of the production of high levels of non-complement fixing serum antibodies and secretory IgA production at the mucosal surfaces.

-14-

The use of an agent in accordance with the sixth aspect of the invention is particularly useful for therapeutic vaccination in diseases in which immunopathological mechanisms are involved. Examples of such diseases are HSV-1, HSV-2, TB and HIV.

The first and sixth aspects of the invention can be combined. In other words, agents such as EtxB can be used simultaneously as an immunomodulator and a therapeutic agent. For example in diseases where immunopathological mechanisms are involved, the use of a vaccine incorporating agents such as EtxB or CtxB may act not only to limit infection, but also to abrogate the pathological disease processes. The immunomodulating agent is thus acting both prophylactically and therapeutically. Examples of infections where vaccination in this way is therefore likely to be of particular value include those caused by the herpes virus family, gastrointestinal and respiratory tract pathogens.

#### Immunomodulation of the antigen processing pathway

##### a) prolonging presentation

The present inventors have also found that when EtxB (or CtxB or VtxB) is used as an immunomodulator, the antigen internalisation and processing pathway is altered. The presence of the B subunit causes prolonged presentation, possibly by altering antigen trafficking inside the antigen presenting cell such that antigen degradation is delayed and therefore maintained over longer periods. This feature of B-subunit associated antigen presentation means that vaccines incorporating an agent in accordance with the present invention will have increased antigen persistence and lead to sustained immunological memory.

According to a seventh aspect of the present invention, there is provided the use of:



-15-

(i) EtxB, CtxB or VtxB free from whole toxin;  
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

5 (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding;

as an immunomodulator in a vaccine, to prolong antigen presentation and give sustained immunological memory in a mammalian subject.

10 According to an eighth aspect of the present invention, there is provided a vaccine composition for use against an infectious disease, comprising an antigenic determinant and a immunomodulator selected from:

15 (i) EtxB, CtxB or VtxB free from whole toxin;  
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

20 (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding;

wherein said antigenic determinant is an antigenic determinant of said infectious disease and wherein the immunomodulator prolongs presentation of the antigenic determinant and gives sustained immunological memory.

**b) intracellular targeting of the antigen to a MHC-I or MHC-II associated pathway**

30 As aforementioned, the antigen and immunomodulator in a therapeutic or prophylactic vaccine may be linked, for example covalently or genetically linked, to form a single effective agent. The present inventors have found that is possible to direct the antigen to  
35 different compartments of the cell and hence to different antigen presentation pathways by altering the

-16-

linkage of the antigen to the immunomodulator.

By linking the antigen or antigenic determinant to the immunomodulator in a certain way, it is possible to facilitate translocation of the antigen across the endosomal membrane into the cytosol. The present inventors predict that this would enhance loading of antigenic peptides on to MHC class I molecules. The use of an antigen-immunomodulator conjugate can therefore be used to specifically enhance the activation of cytotoxic T cells (CTL). Induction of CTL is beneficial for the prevention and treatment of many diseases especially those caused by viruses, intracellular bacteria and parasites.

The linkage of the antigen-immunomodulator conjugate can also be chosen so that the antigen is delivered into the nucleus.

According to a ninth aspect of the present invention there is provided a conjugate comprising an antigen or antigenic determinant and an immunomodulator selected from:

- (i) EtxB, CtxB or VtxB free from whole toxin;
- (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
- (iii) an agent which has an effect on vesicular internalisation mediated by GM1-binding or Gb3 binding.

According to a tenth aspect of the present invention there is provided a vaccine composition for use against an infectious disease, which infectious disease is caused by an infectious agent, which vaccine composition comprises a conjugate of an antigen or antigenic determinant and an immunomodulator selected from:

- (i) EtxB, CtxB or VtxB free from whole toxin;
- (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB

-17-

having Gb3-binding activity; or

(iii) an agent which has an effect on vesicular internalisation mediated by GM1-binding or G3b binding;

wherein said antigen or antigenic determinant is  
5 an antigen or antigenic determinant of said infectious agent.

The antigen or antigenic determinant may be linked to the immunomodulator by a variety of methods including genetic linkage or chemical conjugation. In  
10 a first preferred embodiment the conjugate is a fusion protein made by genetic linkage of the antigen or antigenic determinant to the immunomodulator. Preferably the antigen or antigenic determinant is genetically linked to the C-terminus of the  
15 immunomodulator. In a second preferred embodiment the antigen or antigenic determinant is chemically conjugated to the immunomodulator. Preferably the antigen or antigenic determinant is conjugated to the immunomodulator using a bifunctional cross-linking  
20 reagent, such as a heterobifunctional cross-linking reagent. More preferably the cross-linking agent is N- $\gamma$ (-maleimido-butyroxy)-succinimide ester (GMBS) or N-succinimidyl-(3-pyridyl-dithio)-propionate (SPDP). The vaccine composition may be administered by a number  
25 of different routes such as intranasal, oral, intra-vaginal, urethral or ocular administration. Intranasal immunisation is preferred.

According to an eleventh aspect of the present invention there is provided the use of:

- 30 (i) EtxB, CtxB or VtxB free from whole toxin;  
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or  
(iii) an agent which has an effect on vesicular  
35 internalisation mediated by GM1-binding or Gb3 binding;  
in a conjugate with antigen or antigenic

-18-

determinant to target the delivery of said antigen or antigenic determinant to the cytosol or nucleus of an antigen presenting cell.

5 According to a twelfth aspect of the present invention there is provided the use of:

- (i) EtxB, CtxB or VtxB free from whole toxin;
- (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
- 10 (iii) an agent which has an effect on vesicular internalisation mediated by GM1-binding or Gb3 binding; in a conjugate with antigen or antigenic determinant to upregulate the presentation of said antigenic determinant, or an antigenic determinant
- 15 derived from said antigen, by MHC class I molecules.

Preferably the use of the conjugate of the twelfth aspect of the invention is used in combination with the use of the agent in accordance with the fifth aspect of the invention to stimulate strong CTL responses and to

20 upregulate mucosal antibody production. This activity would be particularly useful in the prevention and treatment of viral infections, for example influenza.

#### EtxB is the preferred immunomodulator

25 It has previously been thought that EtxB and CtxB have similar properties. However, the present inventors have found that rEtxB is a more potent and efficient immunomodulator than rCtxB. Hence the preferred immunomodulator is EtxB, or agents which

30 mimic the effects of EtxB.

#### EBV

EBV is one of the eight known human herpes viruses. Infection usually occurs in early childhood;

35 however, clinical symptoms are usually weak or undetectable at this stage. Primary infection with EBV

-19-

later in life is associated with infectious mononucleosis (IM), which is the second most frequent disease in adolescence in the US. EBV also has oncogenic potential. There is a strong link between EBV and endemic Burkitt's lymphoma (BL) and undifferentiated nasopharyngeal carcinoma (NPC). Also, a large proportion of lymphomas that occur in immunocompromised patients are caused by EBV, and an association has been shown to exist between certain Hodgkin's lymphomas and EBV.

Latently EBV-infected cells express a small number of so-called "latent" proteins. These include six nuclear proteins (EBNAs 1, 2, 3A, 3B, 3C and -LP), three integral membrane proteins (LMP-1, 2A and 2B) and two non-polyadenylated virus derived RNAs (EBERs) with a role in RNA splicing.

EBV latent membrane protein 1 (LMP-1) is present in the plasma membrane of infected cells. It is also expressed in nasopharyngeal carcinomas (NPCs) and EBV-positive Hodgkin's lymphomas (HD) which indicates a role for LMP-1 in the development of these tumours. The LMP-1 gene can alter the phenotype of uninfected cells causing the upregulation of cell surface activation markers, promoting cell proliferation. LMP-1 can also alter signalling pathways and has anti-apoptotic effects. An cellular immune response directed against this viral antigen has not been demonstrated with any degree of certainty in either healthy carriers or tumour patients.

Many animal viruses have evolved mechanisms to avoid detection by the host immune system. Commonly, these mechanisms involve interference with the TAP-associated peptide translocation system. It is thought that EBV has also evolved similar mechanisms to avoid immune system detection, thus allowing its persistence in the host. This explains why certain cellular immune

-20-

responses are not detectable to the EBV latent protein EBNA1 and could explain the apparent absence of such responses against LMP1.

5 According to an thirteenth aspect of the invention there is provided a vaccine composition which comprises:

a) one of the following agents:

- (i) EtxB, CtxB or VtxB free from whole toxin;
- (ii) an agent other than EtxB or CtxB, having  
10 GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
- (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding; and

15 b) an EBV antigen  
for use in the treatment and/or prevention of EBV-associated diseases.

In particular the vaccine composition of the thirteenth aspect of the invention comprises EtxB, CtxB, or an agent other than EtxB or CtxB which has  
20 GM1-binding activity.

According to a fourteenth aspect of the invention there is provided a therapeutic composition which comprises:

- (i) EtxB, CtxB or VtxB free from whole toxin;
- (ii) an agent other than EtxB or CtxB, having  
25 GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
- (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3  
30 binding;

for use in the treatment of EBV-associated diseases.

35 In particular the therapeutic composition of the fourteenth aspect of the invention comprises EtxB, CtxB, or an agent other than EtxB or CtxB which has

-21-

GM1-binding activity.

Based on the knowledge that EtxB cocaps with LMP1, and that EtxB promotes fragmentation of LMP-1, it is theorised that EtxB (and other agents like CtxB having GM1 binding activity) will be useful to stimulate anti-EBV immune responses. This activity has applications in vaccines to prevent EBV associated diseases, and in therapeutic treatments to treat such diseases once they have developed.

Without wishing to be bound by theory, it is believed that when EtxB cocaps with LMP-1 the antigen is processed by a different intracellular route, which enables the antigen to by-pass the normal processing route which is blocked by the virus. The antigen is thus presented efficiently on the cell surface. The action of EtxB may also cause different epitopes of the antigen to be presented at the cell surface, from those which are presented if the antigen were processed by the conventional route.

The vaccine of the thirteenth aspect of the invention may be used to prevent infection by EBV, or development of EBV-associated diseases in EBV-infected individuals. The vaccine may also comprise a separate adjuvant, or the agent (such as EtxB or CtxB) can act as an adjuvant in its own right.

The agents specified in the fourteenth aspect of the present invention may be used alone (i.e. without antigen) in the treatment of a EBV-associated disease which has already developed in a subject.

The preferred agent for use in the thirteenth and fourteenth aspects of the invention is EtxB.

The EBV antigen is an antigen derivable from EBV itself or an antigen which is caused to be expressed by an EBV-infected host cell by the action of EBV.

Preferably the antigen is an EBV latent membrane protein. Particularly preferred are the antigens LMP-

-22-

1, LMP-2A, LMP-2B, and EBNA-1 as well as antigenic fragments thereof. The antigen may be isolated directly from EBV infected cells, or be made by synthetic or recombinant means.

5           The thirteenth and fourteenth aspects of present invention are particularly suited for the treatment and/or prevention of the following diseases: infectious mononucleosis, Burkitt's lymphoma, nasopharyngeal carcinomas, and Hodgkin's lymphomas. It is believed  
10 that these aspects of the invention will be particularly suited to the treatment and/or prevention of nasopharyngeal carcinomas and Hodgkin's lymphomas.

          The vaccine or the therapeutic composition according to the thirteenth and fourteenth aspects of  
15 the invention may be used to prevent development of, or treat, an EBV-associated disease in a mammalian subject, by administration of an immunologically effective amount to the subject.

          The mammalian subject may be, for example, a  
20 healthy EBV-infected or uninfected individual, an immunodeficient individual, or an individual with an EBV-associated disease.

          The vaccine may be administered by any suitable route. The agent and the antigen may be co-  
25 administered to the mammalian subject or administered separately. The agent and the antigen may be separate or linked, for example covalently or genetically linked, to form a single effective agent.

### 30 GM-1 and Gb3-associated signalling

          Without wishing to be bound by theory, it is believed that GM1 or Gb3 binding may trigger intracellular signalling directly or indirectly. The present inventors have also found evidence which  
35 suggests that EtxB interacts with at least one other receptor which is involved in the GM1 associated



-23-

intracellular signalling event. It may be that binding of EtxB (or CtxB) to GM1 facilitates binding to a protein, which protein triggers intracellular signalling. It is not known what specifically triggers the signalling event, it may be phosphorylation of GM1 or the protein. When EtxB/CtxB binds GM1 on the cell surface, bound GM1 is internalised in vesicles (Williams et al (1999) Immunology Today 20;95-101).

GM1 and other glycolipids (such as Gb3) are known to be preferentially located in "membrane rafts" in which key protein receptors are also found. It is therefore possible that internalisation of GM1 as a result of B-subunit binding causes cocapping of such proteins leading to their being triggered to mediate intracellular signalling events.

#### Definitions

An adjuvant is a substance which non-specifically enhances the immune response to an antigen, as distinct from a vaccine carrier, the purpose of which is to target the antigen to a desired site. The term "immunomodulator" is used herein to indicate an agent which acts, like an adjuvant, to stimulate certain immune responses, but which also directs the immune response in a particular direction.

The term "coadministration" is used to mean that the site and time of administration of the antigen and immunomodulator are such that the necessary immune response is stimulated. Thus, while the antigen and the immunomodulator may be administered at the same moment in time and at the same site, there may be advantages in administering the antigen at a different time and/or at a different site from the immunomodulator. For example, antigen and immunomodulator may be administered together in a first step and then the immune response may be boosted in a

-24-

second step by administration of antigen alone.

The term "antigenic determinant" as used herein refers to a site on an antigen which is recognised by an antibody or T-cell receptor. Preferably it is a short peptide derived from or as part of a protein antigen, however the term is also intended to include glycopeptides and carbohydrate antigenic determinants. The term also includes modified sequences of amino acids or carbohydrates which stimulate responses which recognise the whole organism.

There are a number of known methods by which it is possible to identify antigenic determinants for a given infectious agent.

For example, potential protective antigens may be identified by elevating immune responses in infected or convalescent patients, in infected or convalescent animals, or by monitoring *in vitro* immune responses to antigen containing preparations. For example,

i) serum samples from infected or convalescent patients or infected or convalescent animals may be screened against whole cell lysates of an infectious agent, or lysates of cells infected by the said agent, by the standard technique of Western blotting to detect those antigen(s) recognised by the immune serum;

ii) serum samples from infected or convalescent patients or infected or convalescent animals may be screened against partial or highly purified antigens from an infectious agent, or lysates of cells infected by the said agent, by the standard techniques of ELISA, in which partial or highly purified antigens are used to coat microtitre wells, or by immunoblotting to detect those antigen(s) recognised by the immune sera;

iii) serum samples from infected or convalescent patients or infected or convalescent animals may be screened against whole cell lysates derived from

-25-

recombinant expression systems encoding one or more antigens of interest, and using the standard techniques of ELISA or Western blotting to detect those antigen(s) recognised by the immune serum;

5           iv) serum samples from infected or convalescent patients or infected or convalescent animals may be screened against an expression library containing cloned genes from the infectious agent of interest, using colony blot immunodetection to identify that  
10       clones expressing antigens, or fragments thereof, that are recognised by the immune serum; or

          v) PBLs from the blood of infected or convalescent patients or PBL's, lymph node cells, spleen cells, or lamina propria cells from infected or convalescent  
15       animals may be cultured *in vitro* in the presence of partial or highly purified antigens derived from either an infectious agent, or lysates of cells infected by the said agent, or a recombinant expression system encoding one or more antigens, so as detect antigen-  
20       specific T-cell proliferative responses.

          Alternatively it is possible to detect gene products which are essential for the *in vivo* survival of pathogens, as exemplified by the technique of signature tagged mutagenesis developed by Holden or the  
25       detection of gene products specifically induced *in vivo*, such as IVET (In Vivo Expression Technology) developed by Mekalanos or differential fluorescence induction developed by Falkow, identify a subset of genes amongst which are likely to potential protective  
30       antigens. Using these methods the gene products may be screened as outlined above. The genes may be cloned into expression vectors and the antigens recovered for inclusion into vaccine formulations together with agents that modulate a glycosphingolipid-associated  
35       activity.

-26-

There are a number of known methods by which it is possible to isolate antigens for a given infectious agent.

5 For example, surface components of an infectious agent comprising one or more potential protective antigens may be extracted from the agent, or from cells infected by the agent, by use of procedures that allow the recovery of the antigens. This may include the use of cell disruption techniques to lyse cells such as  
10 sonication and/or detergent extraction. Centrifugation, ultrafiltration or precipitation may be used on collected antigen preparations. The antigen preparation containing HSV-1 glycoproteins described in Richards et al., (1998) J. Infect. Dis. 177;1451-7,  
15 exemplifies such a method.

Also, antigens of an infectious agent, or from cells infected by a said agent may be extracted by a variety of procedures, including but not limited to, urea extraction, alkali or acid extraction, or  
20 detergent extraction and then subjected to chromatographic separation. Material recovered in void or elution peaks comprising one or more potential protective antigens may used in vaccine formulations.

Alternatively, genes encoding one or more  
25 potential protective antigens may be cloned into a variety of expression vectors suitable for antigen production. These may include bacterial or eukaryotic expression systems, for example *Escherichia coli*, *Bacillus spp.*, *Vibrio spp.* *Saccharomyces cerevisiae*,  
30 mammalian and insect cell lines. Antigens may be recovered by conventional extraction, separation and/or chromatographic procedures.

The terms "CtxB", "CtxB" and "VtxB" as used herein include natural and recombinant forms of the molecule.  
35 The recombinant form is particularly preferred. The recombinant form of the molecule may be produced by a

-27-

method in which the gene or genes coding for the specific polypeptide chain (or chains) from which the protein is formed, is inserted into a suitable vector and then used to transfect a suitable host. For example, the gene coding for the polypeptide chain from which the EtxB assemble may be inserted into, for example, plasmid pMM68, which is then used to transfect host cells, such as *Vibrio sp.60*. The protein is purified and isolated in a manner known per se. Mutant genes expressing active mutant CtxB, EtxB or VtxB protein may be produced by known methods from the wild type gene.

The terms "CtxB", "EtxB" and "VtxB" also include mutant molecules and other synthetic molecules (containing parts of CtxB, EtxB or VtxB) which retain the capacity to bind GM1 or Gb3 or the capacity to mimic the effects of binding to GM1 or Gb3.

Agents other than EtxB and CtxB which retain GM1 binding activity, and agents other than VtxB which retain Gb3 binding activity include antibodies which bind GM1 or Gb3.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc. may be immunized by injection with GM1 or Gb3 or any derivative or homologue thereof. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminium hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (Bacilli Calmette-Guerin) and *Corynebacterium parvum* are potentially useful human adjuvants.

Humanised monoclonal antibodies may be preferred in the present invention. Monoclonal antibodies may be

-28-

prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Koehler and Milstein (1975 Nature 256:495-497), the human B-cell hybridoma technique (Kosbor et al (1983) Immunol Today 4:72; Cote et al (1983) Proc Natl Acad Sci 80:2026-2030) and the EBV-hybridoma technique (Cole et al (1985) Monoclonal Antibodies and Cancer Therapy, Alan R Liss Inc, pp 77-96). In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al (1984) Proc Natl Acad Sci 81:6851-6855; Neuberger et al (1984) Nature 312:604-608; Takeda et al (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies (US Patent No. 4,946,779) can be adapted to produce target interaction component specific single chain antibodies.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al (1989, Proc Natl Acad Sci 86: 3833-3837), and Winter G and Milstein C (1991; Nature 349:293-299).

Antibody fragments which contain specific binding sites for GM1 or Gb3 may also be generated. For example, such fragments include, but are not limited to, the F(ab')<sub>2</sub> fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the

-29-

disulfide bridges of the F(ab')<sub>2</sub> fragments.

Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse WD et al (1989) Science 256:1275-128 1).

Peptide libraries or organic libraries may be made by combinatorial chemistry and then screened for their ability to bind GM1/Gb3. Synthetic compounds, natural products, and other sources of potentially biologically active materials can be screened in a number of ways deemed to be routine to those of skill in the art.

GM1 or Gb3 or fragments thereof can be used for screening peptides or molecules in any of a variety of screening techniques. The molecule may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition of activity or the formation of binding complexes between GM1 or Gb3 and the agent being tested may be measured.

Another way of determining binding to GM1/Gb3 would be by using purified GM1/Gb3 to coat microtiter plates. Following blocking, the agent under investigation is applied to the plate and allowed to interact prior to washing and detection with specific antibodies to said agent. Conjugation of the antibodies either directly or indirectly to an enzyme or radiolabel allows subsequent quantification of binding either using colorimetric or radioactivity based methods (ELISA or RIA respectively).

Another way of determining binding to GM1/Gb3 would be by binding the saccharide moiety of GM1/Gb3 to a suitable column matrix in order to allow standard affinity chromatography to be performed. Removal of known compounds applied to the column from the diluent would be used as evidence for binding activity, or alternatively, where mixtures of compounds are applied to the column, elution and subsequent analysis would

-30-

determine the properties of the ganglioside binding agent. In the case of proteins, analysis would involve peptide sequencing and tryptic digest mapping followed by comparisons with available databases. In the event  
5 that eluted proteins cannot be identified in this way then standard biochemical analysis, for example mass determination by laser desorption mass spectrometry would be used to further characterise the compound. Non-proteins eluted from GM1-affinity columns would be  
10 analysed by HPLC and mass spectrometry of single homogenous peaks.

Another way of determining the ability to bind to GM1/Gb3 and the precise affinity of the interaction would be by using plasmon surface resonance as  
15 previously reported [Kuziemko et al (1996) Biochem 35:6375-6384].

Alternatively, phage display can be employed in the identification of candidate agents which bind GM1 or Gb3.  
20 Phage display is a protocol of molecular screening which utilises recombinant bacteriophage. The technology involves transforming bacteriophage with a gene that encodes an appropriate ligand (in this case a candidate agent) capable of reacting with GM1/Gb3 (or a  
25 derivative or homologue thereof) or the nucleotide sequence (or a derivative or homologue thereof) encoding same. The transformed bacteriophage (which preferably is tethered to a solid support) expresses the appropriate ligand (such as the candidate agent)  
30 and displays it on their phage coat. The entity or entities (such as cells) bearing the target molecules which recognises the candidate agent are isolated and amplified. The successful candidate agents are then characterised. Phage display has advantages over  
35 standard affinity ligand screening technologies. The phage surface displays the candidate agent in a three



-31-

dimensional configuration, more closely resembling its naturally occurring conformation. This allows for more specific and higher affinity binding for screening purposes.

5           Another technique for screening provides for high throughput screening of agents having suitable binding affinity to GM1 or Gb3 and is based upon the method described in detail in WO 84/03564. In summary, large numbers of different small peptide test compounds are  
10 synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test agents are reacted with the target interaction component fragments and washed. A bound target interaction component is then detected - such as by appropriately adapting  
15 methods well known in the art. A purified target interaction component can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on  
20 a solid support.

          In all aspects of the invention, the agent having GM1-binding activity or Gb3 binding activity may also be capable of cross-linking GM1 or Gb3 receptors. EtxB is one such agent which is capable of cross-linking GM1  
25 receptors by virtue of its pentameric form.

          There are various methods for identifying agents which have an effect on intracellular signalling events mediated by GM1/Gb3 binding but which do not themselves bind GM1 or Gb3. For example, if an agent is shown to  
30 upregulate CD25 or MHC class II on B cells, or to upregulate CD25 or promote apoptosis of CD8+ T cells, or to upregulate IL-10 secretion by monocytes, but the agent is shown not to bind GM1 or Gb3 (by, for example, one of the binding assays described above), then it can  
35 be concluded that the agent is capable of mimicking the effect of GM1/Gb3 binding.

-32-

The invention will now be illustrated by reference to the accompanying drawings and the following examples.

The examples refer to the figures in which:

5        Figure 1: shows the stimulation of total Ig and IgA in the serum (MS) and IgA in the eye washings (EW) in mice immunised with HSV-1 glycoproteins/rEtxB.

10       Figure 2: shows T cell proliferation of (mesenteric lymph node) MLN or (cervical lymph node) CLN lymphocytes in mice immunised with HSV-1/rEtxB.

      Figure 3: shows T cell proliferation of cells from MLN and CLN of mice immunised intranasally with HSV-1 Gp in the presence of 1-20 $\mu$ g EtxB.

15       Figure 4: shows the level of anti-HSV-1 serum Ig in mice following administration of HSV-1 glycoproteins three times at 10 day intervals with variable amounts of rEtxB or rCtxB as adjuvant.

20       Figure 5: shows the reduction in virus shedding, clinical disease and latency in mice immunised with HSV-1/rEtxB.

      Figure 6: shows the Ig isotype distribution in MS following infection with HSV-1 or immunisation with HSV-1 Gp in the presence of EtxB or CtxB as immunomodulator.

25       Figure 7: shows the distribution of Ig subclasses following intranasal administration of HSV-1 Gp with either rEtxB or rCtxB as immunomodulator.

30       Figure 8: shows the immunogenic effect of different amounts of rEtxB or rCtxB on the level of HSV-1 specific IgA in eye washings following administration with HSV-1 glycoproteins.

35       Figure 9: shows serum immunoglobulin response following immunisation of mice with HSV-1 or mock glycoproteins (gp) alone or in the presence of adjuvant.

      Figure 10: shows mucosal IgA in eye washings

-33-

following intranasal immunisation of mice with HSV-1 or mock glycoproteins alone or in the presence of adjuvant.

5 Figure 11: shows mucosal IgA in vaginal washings following intranasal immunisation of mice with HSV-1 or mock glycoproteins (gp) alone or in the presence of adjuvant.

10 Figure 12: shows the level of HSV-1-specific immunoglobulin in sera from mice immunised with HSV-1 glycoproteins in the presence of different doses of rEtxB as adjuvant.

Figure 13: shows the level of IgA in eye washings of mice immunised with HSV-1 glycoproteins in the presence of varying concentrations of rEtxB.

15 Figure 14: shows the level of IgA in vaginal washings of mice immunised with HSV-1 glycoproteins in the presence of varying concentrations of rEtxB

20 Figure 15: shows IgG subclass distribution of the serum antibody response to HSV-1 following intranasal immunisation with Ctx/CtxB or rEtxB or ocular infection with HSV-1.

25 Figure 16: shows cytokine production from cultures of lymph node cells taken from mice which were either infected with HSV-1 by ocular scarification, or were immunised by intranasal administration of HSV-1 glycoproteins with Ctx/CtxB or rEtxB as adjuvant.

30 Figure 17: shows the level of protection against ocular HSV-1 infection in mice immunised intranasally with a mixture of HSV-1 or mock glycoproteins in the presence of rEtxB as immunomodulator.

Example 1: rEtxB can be used in conjunction with HSV-1 Gp for immunisation.

35 Mice were immunised intranasally three times with 10µg HSV-1 glycoproteins (Gp) with either 10 or 20µg rEtxB. Controls were either unmanipulated or given a

-34-

mock preparation of viral glycoprotein (mock) derived from HIV-uninfected tissue culture cells. Antibody levels are expressed as a percentage of post-infection levels. The production of total Ig and IgA in the serum and IgA in eye washings was stimulated by HSV-1 glycoproteins/rEtxB (Figure 1). The present inventors have also shown that doses of rEtxB as low as 0.1 $\mu$ g are also effective at stimulating such responses.

Also, T-lymphocytes from immunised mice from the cervical lymph node (which is local to the vaccination site) and from the mesenteric lymph node (which is distant to the vaccination site) were shown to proliferate when cultured in vitro with HSV-1, but not when cultured in vitro with mock HSV-1 Gp or without antigen (Figure 2).

The proliferation in response to HSV-1 Gp of T lymphocytes from MLN and CLN of mice immunised with HSV-1 Gp and varying amounts of EtxB is shown in Fig 3.

The production of Anti-HSV-1 serum Ig in mice following administration of HSV-1 glycoproteins at three day intervals with varying amounts of EtxB (or CtxB) is shown in Figure 4.

Finally, mice immunised with HSV-1 and rEtxB were shown to have a decrease in virus shedding following corneal scarification with HSV-1 (Figure 5a), and a decrease in local spreading (oedema and lid disease), spreading to the trigeminal ganglion (zosteriform infection), spreading to the central nervous system (encephalitis) and latency compared to controls (5b).

Example 2: rCtxB and rEtxB act as immunomodulators.

When EtxB is used as an immunomodulator, the Ig isotype distribution is skewed (Figure 6). The distribution of Ig subclasses is different depending on whether rCtxB or rEtxB is used as an immunomodulator (Figure 7).

-35-

Example 3: rEtxB is a more efficient immunomodulator than rCtxB.

5 The levels of HSV-specific IgA (Figure 8) and is greater following stimulation with rEtxB/HSV-1 Gp than rCtxB/HSV-1 Gp.

Example 4: (Figure 9)

10 Mice were immunised three times intranasally with HSV-1 glycoproteins alone, a mock preparation of HSV-1 glycoproteins (prepared by taking uninfected tissue culture cells and subjecting them to identical treatment regimes as those employed for the isolation and purification of HSV-1 proteins), or HSV-1 glycoproteins in combination with a variety of putative  
15 mucosal adjuvants. In each case the dose of HSV-1 glycoproteins was 10µg per immunisation, and these were combined with 10µg of recombinant EtxB, or CtxB as adjuvant, or a mixture of 0.5µg of Ctx and 10µg CtxB. Three weeks after the final immunisation, blood samples  
20 were collected and total anti-HSV-1 antibodies were measured by ELISA. The quantities of antibodies are expressed as a percentage of the levels stimulated following ocular infection induced by scarification with 10<sup>5</sup> pfu HSV-1 strain SC16. The data (shown in  
25 Figure 9) shows that the strongest serum antibody response is stimulated when antigen is combined with a mixture of whole Ctx and CtxB. However, a high level response is also stimulated when rEtxB is used as an adjuvant. In contrast, rCtxB is a very weak adjuvant.

30

Example 5: (Figure 10)

Mice were immunised as described in example 4. Secretory IgA production in the eye was assessed by taking washings of the tears over consecutive days and  
35 these samples were then pooled and subjected to ELISA analysis using a specific anti-IgA detecting antibody.

-36-

The quantities of antibodies are expressed as a percentage of the levels stimulated following ocular infection induced by scarification with  $10^5$  pfu HSV-1 strain SC16. The data clearly demonstrates (Figure 10) that high levels of secreted anti-HSV-1 antibodies are produced following immunisation in the presence of either Ctx/CtxB or EtxB. In contrast to the results from analysis of serum antibody responses, there was no difference in the level of antibodies in the eye between those animals immunised with Ctx/CtxB or EtxB as adjuvants. As with serum antibody, there was clear evidence that rCtxB is a very poor adjuvant.

Example 6: (Figure 11)

Mice were immunised as described in example 4. Secretory IgA production in the vagina was assessed by taking washings from the genital tract over consecutive days and these samples were then pooled and subjected to ELISA analysis using a specific anti-IgA detecting antibody. The quantities of antibodies are expressed as endpoint titres which were calculated by linear regression analysis. The data clearly demonstrates that high levels of secreted anti-HSV-1 antibodies are produced in distant mucosal sites following immunisation in the presence of either Ctx/CtxB or EtxB. In the vagina, the highest levels of antibodies were released following immunisation in the presence of rEtxB. Lower levels were released following immunisation with Ctx/CtxB and very little secretion was triggered by the use of rCtxB as adjuvant.

Example 7: (Figure 12)

Mice were immunised three times intranasally with HSV-1 glycoproteins (10 $\mu$ g) either alone or in the presence of escalating doses of rEtxB as adjuvant. Three weeks after the final immunisation blood was

-37-

taken, and the levels of anti-HSV-1 antibodies were assessed by ELISA. The quantities of antibodies are expressed as a percentage of the levels stimulated following ocular infection induced by scarification with  $10^5$  pfu HSV-1 strain SC16. The data clearly demonstrates that the capacity of rEtxB to trigger antibody responses to heterologous added antigens is a dose dependent phenomenon with maximal responsiveness occurring at approximately 20-50 $\mu$ g of rEtxB. Further, it is clear that at doses of 20 $\mu$ g rEtxB and above, the level of anti-HSV-1 antibodies stimulated by intranasal infection is comparable or greater than that stimulated by a live virulent virus infection.

Example 8: (figure 13)

Mice were immunised as described in example 7. Secretory IgA production in the eye was assessed by taking washings of the tears over consecutive days and these samples were then pooled and subjected to ELISA analysis using a specific anti-IgA detecting antibody. The quantities of antibodies are expressed as a percentage of the levels stimulated following ocular infection induced by scarification with  $10^5$  pfu HSV-1 strain SC16. The data demonstrates that maximal IgA responses in the eye are stimulated when HSV-1 glycoproteins are given in combination with 20 $\mu$ g of rEtxB or above. At this dose the levels of IgA production are nevertheless lower than those triggered during virus infection of the eye.

30

Example 9: (Figure 14)

Mice were immunised as described in example 7. Secretory IgA production in the vagina was assessed by taking washings from the genital tract over consecutive days and these samples were then pooled and subjected to ELISA analysis using a specific anti-IgA detecting

35

-38-

antibody. The quantities of antibodies are expressed as endpoint titres which were calculated by linear regression analysis. The data shows that optimal anti-HSV-1 responses are stimulated in the vagina when 20µg or above of rEtxB is used as an adjuvant.

Example 10: (Figure 15)

Mice were either infected with  $10^5$  pfu HSV-1 strain SC16 by scarification into the cornea or immunised three times intranasally with 10µg HSV-1 glycoproteins in combination with Ctx/CtxB or rEtxB. Three weeks after the final inoculation, serum was taken and was analysed by ELISA for the presence of IgG1 and IgG2a against HSV-1. The quantities of antibodies are expressed as endpoint titres which were calculated by linear regression analysis (fig. 7a). The data clearly shows that the nature of the antibody response to HSV-1 is influenced by the way in which the antigens are presented to the immune system. Infection with HSV-1 predominantly activates Th1 associated antibody production, as characterised by the high levels of the complement fixing antibody isotype, IgG2a. Infection stimulates relatively low levels of the Th2 associated IgG isotype, IgG1. This profile of the immune response is clearly visible when the data is expressed as a ratio of IgG1:IgG2a as shown in fig. 7b. The ratio is substantially less than 1 following infection. Intranasal immunisation in the presence of Ctx/CtxB as adjuvant triggers the release, predominantly, of Th2 associated IgG1. Significant levels of IgG2a are also produced suggesting that Ctx/CtxB causes activation of Th1 and Th2 cells. The activation of both responses and the relative dominance of Th2 is reflected in the IgG1:IgG2a ratio which is approximately 3. Interestingly the nature of the response to HSV-1 stimulated by rEtxB as adjuvant is



-39-

almost exclusively Th2 dominated. High levels of IgG1 are produced with only very low amounts of IgG2a. This strong bias toward Th2 responsiveness is reflected in an IgG1:IgG2a ratio of approximately 9.

5

Example 11: (Figure 16)

Mice were either infected with  $10^5$  pfu HSV-1 strain SC16 by scarification into the cornea or immunised three times intranasally with  $10\mu\text{g}$  HSV-1 glycoproteins in combination with Ctx/CtxB or rCtxB. 10 Three weeks after the final inoculation lymph nodes were removed from animals and were used to generate single cell suspensions that were cultured either in the presence of killed HSV-1 or a mock preparation of 15 virus from non-infected tissue culture cells. On days 4 to 7 of the cultures, samples of cells were removed and subjected to cELISA analysis to reveal the secretion of cytokines. The data clearly shows that T-cells in the cultures were capable of responding to 20 HSV-1, but not significantly to mock virus preparations. Lymph node cells taken from mice which had been infected with HSV-1 produced predominantly the Th1 associated cytokine  $\gamma$ -interferon ( $\gamma$ -IFN). Lymph node cells taken from animals that were immunised 25 intranasally produced high levels of the Th2 associated cytokines, IL-4 and IL-10. In addition, both Ctx/CtxB and rCtxB had led to the activation of T-cells which secreted  $\gamma$ IFN upon in vitro stimulation with HSV-1. This indicates that although the response to these 30 adjuvants is dominated by the production of Th2 cytokines some Th1 activation also occurs. These findings are consistent with those from the analysis of antibody responses.

-40-

**CLAIMS**

1. The use of:
  - (i) EtxB, CtxB or VtxB free from whole toxin;
  - (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or
  - (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding;
- 10 as an immunomodulator for a vaccine against infectious diseases.
2. The use according to claim 1, wherein the immunomodulator is EtxB free from whole toxin.
3. The use according to claim 1 or 2, wherein
- 15 the infectious disease is one for which the infectious agent is a member of the herpes virus family.
4. The use according to claim 3, wherein the infectious disease is caused by an infectious agent, and the infectious agent is selected from the group
- 20 consisting of HSV-1, HSV-2, EBV, VZV, CMV, HHV-6, HHV-7 and HHV-8.
5. The use according to claim 4, wherein the infectious agent is selected from the group consisting of HSV-1, HSV-2, CMV or EBV.
- 25 6. The use according to claim 1 or 2, wherein the infectious disease is caused by an infectious agent, and the infectious agent is an influenza virus.
7. The use according to claim 1 or 2, wherein the infectious disease is caused by an infectious
- 30 agent, and the infectious agent is a parainfluenza virus.
8. The use according to claim 1 or 2, wherein the infectious disease is caused by an infectious agent, and the infectious agent is a respiratory
- 35 syncytial virus.
9. The use according to claim 1 or 2, wherein

-41-

the infectious disease is caused by an infectious agent, and the infectious agent is a hepatitis virus.

10. The use according to claim 9, wherein the infectious agent is selected from the group consisting of hepatitis A, B, C and D viruses.

11. The use according to claim 10, wherein the infectious agent is a hepatitis A virus or a hepatitis C virus.

12. The use according to claim 1 or 2, wherein the infectious disease is meningitis.

13. The use according to claim 12, wherein the infectious disease is caused by an infectious agent, and the infectious agent is selected from the group consisting of *Neisseria meningitidis*, *Haemophilus influenzae* type B and *Streptococcus pneumoniae*.

14. The use according to claim 1 or 2, wherein the infectious disease is pneumonia or a respiratory tract infection.

15. The use according to claim 14, wherein the infectious disease is caused by an infectious agent, and the infectious agent is selected from the group consisting of *Streptococcus pneumoniae*, *Legionella pneumophila* and *Mycobacterium tuberculosis*.

16. The use according to claim 1 or 2, wherein the infectious disease is a sexually-transmitted disease.

17. The use according to claim 16, wherein the infectious disease is caused by an infectious agent, and the infectious agent is selected from the group consisting of *Neisseria gonorrhoeae*, HIV-1, HIV-2 and *Chlamydia trachomatis*.

18. The use according to claim 1 or 2, wherein the infectious disease is a gastrointestinal disease.

19. The use according to claim 18, wherein the infectious disease is caused by an infectious agent,

-42-

and the infectious agent is selected from the group consisting of enteropathogenic, enterotoxigenic, enteroinvasive, enterohaemorrhagic and enteroaggregative *E.coli*, rotavirus, *Salmonella enteritidis*, *Salmonella typhi*, *Helicobacter pylori*,  
5 *Bacillus cereus*, *Campylobacter jejuni* and *Vibrio cholerae*.

20. The use according to claim 1 or 2, wherein the infectious disease is a superficial infection.

10 21. The use according to claim 20, wherein the infectious disease is caused by an infectious agent, and the infectious agent is selected from the group consisting of *Staphylococcus aureus*, *Streptococcus pyogenes* and *Streptococcus mutans*.

15 22. The use according to claim 1 or 2, wherein the infectious disease is a parasitic disease.

23. The use according to claim 22, wherein the infectious disease is caused by an infectious agent, and the infectious agent is selected from the group  
20 consisting of malaria, *Trypanasoma* spp., *Toxoplasma gondii*, *Leishmania donovani* and *Oncocerca* spp.

24. A vaccine composition for use against an infectious disease, which infectious disease is caused by an infectious agent, wherein the vaccine composition  
25 comprises an antigenic determinant and an immunomodulator selected from:

- (i) EtxB, CtxB or VtxB free from whole toxin;
- (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having  
30 Gb3-binding activity; or
- (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding;

wherein said antigenic determinant is an antigenic

-43-

determinant of said infectious agent.

25. A vaccine composition according to claim 24 in which the infectious disease is HSV-1 infection and wherein the antigenic determinant is an antigenic determinant of HSV-1.

26. A vaccine composition according to claim 24 or 25 in which the immunomodulator is EtxB free from whole toxin.

27. A vaccine composition according to claim 24, 25 or 26 in which the immunomodulator and the antigenic determinant are separate moieties.

28. A vaccine composition according to claim 24, 25 or 26 in which the immunomodulator and the antigenic determinant are linked by a bifunctional crosslinking reagent.

29. A kit for vaccination of a mammalian subject against an infectious disease, which kit comprises:

a) one of the following agents:

(i) EtxB, CtxB or VtxB free from whole toxin;  
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

(iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding; and

b) an antigenic determinant which is an antigenic determinant of the infectious disease, for coadministration with the said vaccine immunomodulator.

30. A method of preventing or treating a disease in a host, which method comprises the step of inoculating said host with a vaccine comprising at least one antigenic determinant and an immunomodulator, where the immunomodulator is:

(i) EtxB, CtxB or VtxB free from whole toxin;  
(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having

-44-

Gb3-binding activity; or

(iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding.

5 31. The use of:

(i) EtxB, CtxB or VtxB free from whole toxin;

(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

10 (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding

to upregulate the production of antibodies at mucosal surfaces.

15 32. The use of:

(i) EtxB, CtxB or VtxB free from whole toxin;

(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

20 (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding;

as an immunomodulator in a vaccine, to prolong antigen presentation and give sustained immunological memory in a mammalian subject.

25 33. A vaccine composition for use against an infectious disease, which infectious disease is caused by an infectious agent, which vaccine comprises an antigenic determinant and a immunomodulator selected from:

30 (i) EtxB, CtxB or VtxB free from whole toxin;

(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

35 (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding

-45-

or Gb3 binding;

wherein said antigenic determinant is an antigenic determinant of said infectious agent and wherein the immunomodulator prolongs presentation of the antigenic determinant and gives sustained immunological memory.

34. The use of:

(i) EtxB, CtxB or VtxB free from whole toxin;

(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

(iii) an agent which has an effect on vesicular internalisation mediated by GM1-binding or Gb3 binding;

in a conjugate with antigen or antigenic determinant to target the delivery of said antigen or antigenic determinant to the cytosol or nucleus of an antigen presenting cell.

35. The use of:

(i) EtxB, CtxB or VtxB free from whole toxin;

(ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or

(iii) an agent which has an effect on vesicular internalisation mediated by GM1-binding or Gb3 binding;

in a conjugate with antigen or antigenic determinant to upregulate the presentation of said antigenic determinant, or an antigenic determinant derived from said antigen, by MHC class I molecules.

36. A vaccine composition which comprises:

a) EtxB, CtxB, or an agent other than EtxB or CtxB which has GM1-binding activity; and

b) an EBV antigen

for use in the treatment and/or prevention of EBV-associated diseases.

37. A therapeutic composition which comprises:

-46-


EtxB, CtxB or an agent other than EtxB or CtxB  
which has GM1-binding activity  
for use in the treatment of EBV-associated  
diseases.



1/15

FIGURE 1


Level of Ig or IgA in MS or IgA in EW compared with control mice following immunisation with HSV-1 or mock Gp preparations with different amounts of rEtxB



2/15

FIGURE 2


T cell proliferation of MLN or CLN lymphocytes from mice given HSV-1 glycoproteins (gp) with 10 $\mu$ g (A), 20 $\mu$ g (B) rEtxB or mock Gp with 20 $\mu$ g rEtxB (C) by the i.n. route cultured *in vitro* with HSV-1, mock or no antigen



3/15

FIGURE 3


Tcell proliferation of cells from MLN and CLN of mice immunised i.n. with HSV-1  
Gp in the presence of 1-20µg EtxB as adjuvant



4/15

FIGURE 4

Anti-HSV-1 serum Ig in mice following administration of HSV-1 glycoproteins three times at 10 day intervals with variable amounts of rEtxB or rCTB as adjuvant



5/15

**Figure 5a. Incidence of virus shedding from the eye following corneal scarification of mice with HSV-1 (SC16)**

Day post infection	10µg rEtxB + HSV-1 gp (%) <sup>1</sup>	20µg rEtxB + HSV-1 gp (%)	20µg rEtxB + mock gp <sup>2</sup> (%)
1	0	30	60
2	60	80	95
3	60	80	95
6	10	0	70
7	10	0	70
8	0	0	10
9	0	0	0

<sup>1</sup> Percentage of animals from which wash fluid from the eye secretions revealed the presence of live viral particles in a plaque assay.

<sup>2</sup> Mock infected animals were given an inoculum of glycoproteins prepared from uninfected tissue culture cells.

**Figure 5b. Clinical disease following corneal scarification of mice with HSV-1 (SC16)**

	Corneal ulcers <sup>2</sup>	Oedema	Lid disease	Zosteriform infection	Encephalitis	Latency <sup>1</sup>		
						TG1	TG2	TG3
10µg rEtxB + HSV-1 gp	80%	0%	0%	0%	0%	22%	11%	0%
20µg rEtxB + HSV-1 gp	70%	0%	0%	0%	0%	80%	10%	0%
20µg rEtxB + mock gp	80%	45%	55%	40%	40%	83%	30%	16%

<sup>1</sup> Latency was determined by extraction of the trigeminal ganglion (TG) from surviving mice 2 months after infection and coculturing with Vero cells. Figures given are for each of the lobes of the TG (TG1, TG2 and TG3).


<sup>2</sup> Figures are percentage of animals showing signs of the described symptoms at any point during acute infection. Each mouse was examined on a daily basis during the first 11 days of infection.

N=15 per group


6/15

**FIG. 6**


**Ig Isotype distribution in MS from mice following infection (pos) or immunisation with HSV-1 Gp in the presence of EtxB or CTB as adjuvant**

**FIG. 7**

**Adjuvant effect of different amounts of rEtxB or rCtB on the level of HSV-1 specific IgA in eye washings following administration with HSV-1 glycoproteins**




**FIG 8. Distribution of subclasses following administration of HSV-1 Gp i.n. with either rEtxB or rCTB as adjuvant**



7/15

FIGURE 9



\* antibody levels were measured by ELISA and are expressed as a percentage of the levels stimulated following ocular infection induced by scarification with  $10^5$  pfu HSV-1 strain SC16.

Ctx/CtxB =  $0.5\mu\text{g}$  Ctx +  $10\mu\text{g}$  CtxB


rETxB =  $10\mu\text{g}$  recombinant EtxB

gp =  $10\mu\text{g}$  HSV-1 or mock glycoproteins as indicated.

8/15

FIGURE 10

**Mucosal IgA in eye washings following intranasal immunisation of mice with HSV-1 or mock glycoproteins (gp) alone or in the presence of adjuvant**




\* antibody levels were measured by ELISA and are expressed as a percentage of the levels stimulated following ocular infection induced by scarification with  $10^5$  pfu HSV-1 strain SC16.  
 Ctx/CtxB =  $0.5\mu\text{g}$  Ctx +  $10\mu\text{g}$  CtxB  
 rEtxB =  $10\mu\text{g}$  recombinant EtxB  
 gp =  $10\mu\text{g}$  HSV-1 or mock glycoproteins as indicated.



9/15

FIGURE 11

**Mucosal IgA in vaginal washings following intranasal immunisation of mice with HSV-1 or mock glycoproteins (gp) alone or in the presence of adjuvant**




\* antibody levels were measured by ELISA and are expressed as end point titres calculated by linear regression analysis  
Ctx/CtxB = 0.5µg Ctx + 10µg CtxB  
rETxB = 10µg recombinant ETxB  
gp = 10µg HSV-1 or mock glycoproteins as indicated.

10/15

FIGURE 12

**Level of HSV-1-specific immunoglobulin in sera from mice immunised with HSV-1 glycoproteins in the presence of different doses of rEtxB as adjuvant**




\* antibody levels were measured by ELISA and are expressed as a percentage of the levels stimulated following ocular infection induced by scarification with  $10^5$  pfu HSV-1 strain SC16.

11/15

FIGURE 13

**Level of IgA in eye washings of mice immunised with HSV-1 glycoproteins in the presence of varying concentrations of rEtxB**




\* antibody levels were measured by ELISA and are expressed as a percentage of the levels stimulated following ocular infection induced by scarification with  $10^5$  pfu HSV-1 strain SC16.

12/15

FIGURE 14

**Level of IgA in vaginal washings of mice immunised with HSV-1 glycoproteins in the presence of varying concentrations of rEtxB**




\* antibody levels were measured by ELISA and are expressed as endpoint titres calculated using linear regression analysis.

13/15


**FIGURE 15**

**IgG subclass distribution of the serum antibody response to HSV-1  
following intranasal immunisation with Ctx/CtxB or rETxB or  
ocular infection with HSV-1**



14/15

FIGURE 16



Cytokines were measured using cELISA and quantities calculated against standard curves prepared using recombinant cytokines. Values are expressed from cultures from mice immunised intranasally with 10µg HSV-1 glycoproteins with either Ctx/CtxB or rETxB as adjuvant, and cultured with whole killed HSV-1 (HSV-1) or identically treated mock virus preparation (Mock antigen).

15/15

FIGURE 17

**Level of protection against ocular HSV-1 infection in mice immunised intranasally with a mixture of HSV-1 or mock glycoproteins in the presence of rEtxB as adjuvant**

Immunisation	Corneal Ulcers	Opacity/ Oedema	Lid Disease	Zosteriform Infection	Encephal- itis	Latency		
						TGI	TGII	TGIII
10µg HSV-1 gp + 10µg rEtxB per dose	69%	10%	0%	3%	0%	22%	11%	0%
10µg mock gp + 10µg rEtxB per dose	80%	68%	74%	72%	50%	83%	30%	16%

 $\chi^2_{n=29}$   
 $\chi^2_{n=30}$

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/12, 38/16, 39/245, 39/385</b>		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/58145</b>
			<b>(43) International Publication Date:</b> 18 November 1999 (18.11.99)
<b>(21) International Application Number:</b> PCT/GB99/01461		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
<b>(22) International Filing Date:</b> 10 May 1999 (10.05.99)		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(30) Priority Data:</b> 9809958.3 8 May 1998 (08.05.98) GB 9811954.8 3 June 1998 (03.06.98) GB 9812316.9 8 June 1998 (08.06.98) GB		<b>(88) Date of publication of the international search report:</b> 3 February 2000 (03.02.00)	
<b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF BRISTOL [GB/GB]; Senate House, Tyndall Avenue, Clifton, Bristol BS8 1TH (GB).			
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HIRST, Timothy, Raymond [GB/GB]; 30 Albert Road, Clevedon, North Somerset BS21 7RR (GB). WILLIAMS, Neil, Andrew [GB/GB]; 16 Old Coach Road, Cross, Axbridge, Somerset BS26 2EF (GB).			
<b>(74) Agent:</b> NASH, David, Allan; Haseltine Lake & Co., Imperial House, 15-19 Kingsway, London WC2B 6UD (GB).			
<b>(54) Title:</b> IMMUNOMODULATORS FOR VACCINES			
<b>(57) Abstract</b> <p>There is disclosed the use of: (i) EtxB, CtxB or VtxB free from whole toxin; (ii) an agent other than EtxB or CtxB, having GM1-binding activity, or an agent other than VtxB having Gb3-binding activity; or (iii) an agent having an effect on intracellular signalling events mediated by GM1-binding or Gb3 binding; as an immunomodulator for a vaccine against infectious diseases.</p>			



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/01461

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-23,30,31,34 and 35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.